EP0861262B1 - Nucleic acid capture moieties - Google Patents

Nucleic acid capture moieties Download PDF

Info

Publication number
EP0861262B1
EP0861262B1 EP96928976A EP96928976A EP0861262B1 EP 0861262 B1 EP0861262 B1 EP 0861262B1 EP 96928976 A EP96928976 A EP 96928976A EP 96928976 A EP96928976 A EP 96928976A EP 0861262 B1 EP0861262 B1 EP 0861262B1
Authority
EP
European Patent Office
Prior art keywords
nucleic acid
duplex
binding
capture moiety
target
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP96928976A
Other languages
German (de)
French (fr)
Other versions
EP0861262A1 (en
EP0861262A4 (en
Inventor
Michael J. Lane
Albert S. Benight
Brian D. Faldasz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Luminex Molecular Diagnostics Inc
Original Assignee
Luminex Molecular Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Luminex Molecular Diagnostics Inc filed Critical Luminex Molecular Diagnostics Inc
Publication of EP0861262A1 publication Critical patent/EP0861262A1/en
Publication of EP0861262A4 publication Critical patent/EP0861262A4/en
Application granted granted Critical
Publication of EP0861262B1 publication Critical patent/EP0861262B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813Hybridisation assays
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813Hybridisation assays
    • C12Q1/6834Enzymatic or biochemical coupling of nucleic acids to a solid phase

Definitions

  • the present invention pertains to methods of detecting nucleic acid sequences.
  • Methods of detecting sequences of nucleic acids are of wide applicability in fields such as medical diagnosis.
  • the target nucleic acid is immobilised on a solid surface, such as nitrocellulose filter.
  • the target is then detected by hybridization with a labelled probe which is complementary to the target.
  • Other methods include those assays generally described as "sandwich assays", such as those disclosed by Dunn et al., Cell 12:33-36 (1977 ); and US Patent 4,563,419 to Ranki.
  • a target nucleic acid is hybridized to a capture probe, and a second, reporter probe complementary to the target but not to the capture probe, is then added. Excess probes are washed away and binding of the reporter probe is measured.
  • the methods of the invention feature nucleic acid capture moieties which are complementary to a target sequence to sensitively and selectively detect target nucleic acid sequences.
  • the invention features a method of capturing a target single-stranded nucleic acid sequence on a solid support, the method comprising the steps of:
  • the method further comprises the step of detecting the presence or absence of hybridization of the target nucleic acid and the nucleic acid capture moiety, such that the target single-stranded nucleic acid is detected.
  • the intermolecular duplex comprises a duplex-binding-ligand binding site; hybridization of the target single-stranded nucleic acid to the nucleic acid capture moiety forms a nicked duplex; the duplex-binding-ligand binding site does not include a nick; the reaction mixture further comprises a duplex-binding ligand; the duplex-binding ligand is sequence-specific; the duplex-binding ligand does not covalently modify any duplex.
  • reaction mixture for promoting hybridization of a nucleic acid hairpin and a target nucleic acid comprising:
  • the methods of the invention are useful in the detection of nucleic acid sequences.
  • the invention features nucleic acid capture moieties for use in detecting target nucleic acids.
  • the methods of the invention can be performed with capture moieties immobilized in multiwell plates; thus, multiple samples can be screened simultaneously.
  • the methods of the invention can easily be automated, at least in part, to speed screening and improve economy.
  • the capture moieties can selectively bind the target sequence, thereby reducing background noise to very low levels.
  • An additional advantage is that the label signal can be amplified to achieve highly sensitive detection.
  • nucleic acid strand refers to a strand of DNA or RNA, or a chimeric DNA-RNA strand, or nucleic acid-like compounds such as peptide nucleic acids.
  • a nucleic acid strand can also include modified DNA or RNA bases, of which many are known in the art.
  • target nucleic acid sequence refers to a nucleic acid sequence which is to be detected.
  • the target nucleic acid sequence can be any nucleic acid strand, as defined above, and in general will be single-stranded or will be made single-stranded by methods known in the art.
  • the target nucleic acid sequence can be obtained from various sources including plasmids, viruses, bacteria, fungi, yeast, plants, and animals, including humans; or the target nucleic acid sequence can be obtained from non-natural sources.
  • the target nucleic acid sequence can be obtained from various organisms or tissues, including fluids such as blood, semen, urine and the like.
  • the target nucleic acid sequence is preferably extracted or purified to remove or reduce contaminating or interfering materials such as proteins or cellular debris. Procedures for such purification or extraction are known in the art, including, for example, those described in Maniatis et al., "Molecular Cloning: A Laboratory Manual", Cold Spring Harbor Laboratory (1989 ), or in Bell et al., Proc. Nat. Acad. Sci. USA (1981), 78:5759-5763 .
  • the methods of the present invention are particularly useful in the detection of nucleic acid sequences associated with infectious diseases, genetic disorders, or cellular conditions such as cancer. The methods of the invention are also useful for the detection of non-natural target nucleic acids, as described in more detail below.
  • adjacent refers to non-overlapping segments of a nucleic acid strand which are not separated by intervening bases.
  • nucleic acid capture moiety which has at least one nucleic acid region which is substantially complementary to a target nucleic acid, and having at least two nucleic acid regions which are capable of forming an intramolecular duplex.
  • nucleic acid capture moiety or simply “capture moiety”, as used herein, refers to a moiety which binds selectively to a target nucleic acid sequence and which can be immobilized on an insoluble support. The capture moiety can be immobilized on the solid support before, simultaneous with, or after capturing the target strand.
  • a capture moiety can "capture" a target nucleic acid by hybridizing to the target and thereby immobilizing the target.
  • the nucleic acid capture moiety comprises a nucleic acid strand which has at least one region which is substantially complementary to a region of the target nucleic acid sequence, and forms a nucleic acid hairpin, as defined below.
  • a capture moiety will be bound to a solid support. Such binding to a solid support may be through a linking moiety which is bound to either the capture moiety or to the solid support.
  • the capture moiety may be labelled, as with, e.g., a radioisotope, a fluorescent moiety, an antibody, an antigen, a lectin, an enzyme, or other labels well known in the art.
  • the target nucleic acid sequence may be so labelled, or, alternatively, labelled secondary probes may be employed.
  • a "secondary probe" is a nucleic acid sequence which is complementary to either a region of the target nucleic acid sequence or to a region of the capture moiety.
  • nucleic acid hairpin refers to a unimolecular nucleic acid-containing structure which comprises at least two mutually complementary nucleic acid regions such that at least one intramolecular duplex can form. Hairpins are described in, for example, Cantor and Schimmel, "Biophysical Chemistry", Part III, p. 1183 (1980 ).
  • the mutually complementary nucleic acid regions are connected through a nucleic acid strand; in these embodiments, the hairpin comprises a single strand of nucleic acid.
  • a region of the capture moiety which connects regions of mutual complementarity is referred to herein as a "loop" or "linker”.
  • a loop comprises a strand of nucleic acid or modified nucleic acid.
  • the linker is not a hydrogen bond.
  • the loop comprises a linker region which is not nucleic-acid-based; however, capture moieties in which the loop region is not a nucleic acid sequence are referred to herein as hairpins.
  • non-nucleic-acid linkers suitable for use in the loop region are known in the art and include, for example, alkyl chains (see, e.g., Doktycz et al. (1993) Biopolymers 33:1765 ).
  • a loop can be a single-stranded region of a hairpin
  • a "single-stranded region" of a hairpin refers to a non-loop region of a hairpin.
  • the loop preferably comprises 2-20 nucleotides, more preferably 3-8 nucleotides.
  • the size or configuration of the loop or linker is selected to allow the regions of mutual complementarity to form an intramolecular duplex.
  • hairpins useful in the present invention will form at least one intramolecular duplex having at least 2 base pairs, more preferably at least 4 base pairs, and still more preferably at least 8 base pairs.
  • the number of base pairs in the duplex region, and the base composition thereof, can be chosen to assure any desired relative stability of duplex formation.
  • the number of base pairs in the intramolecular duplex region will generally be greater than about 4 base pairs.
  • the hairpin described in Example 3, infra has a 16-base-pair duplex region, conferring exceptional stability on the intramolecular duplex.
  • the intramolecular duplex will generally not have more than about 40 base pairs. In preferred embodiments, the intramolecular duplex is less than 30 base pairs, more preferably less than 20 base pairs in length.
  • a hairpin may be capable of forming more than one loop.
  • a hairpin capable of forming two intramolecular duplexes and two loops is referred to herein as a "double hairpin".
  • a hairpin will have at least one single-stranded region which is substantially complementary to a target nucleic acid sequence.
  • substantially complementary means capable of hybridizing to a target nucleic acid sequence under the conditions employed.
  • a "substantially complementary" single-stranded region is exactly complementary to a target nucleic acid sequence.
  • hairpins useful in the present invention have a target-complementary single-stranded region having at least 5 bases, more preferably at least 8 bases.
  • the hairpin has a target-complementary single-stranded region having fewer than 30 bases, more preferably fewer than 25 bases.
  • the target-complementary region will be selected to ensure that target strands form stable duplexes with the capture moiety.
  • the capture moiety is used to detect target strands from a large number of non-target sequences (e.g., when screening genomic DNA)
  • the target-complementary region should be sufficiently long to prevent binding of non-target sequences.
  • a target-specific single-stranded region may be at either the 3' or the 5' end of the capture moiety strand, or it may be situated between two intramolecular duplex regions (for example, between two duplexes in a double hairpin).
  • Hairpins useful in the present invention have the structure A-B-C-D wherein A is a target-specific nucleic acid sequence; B and D are nucleic acid sequences which are capable of hybridizing to each other to form an intramolecular duplex; and C is a linker.
  • immobilized hairpins have the general structure illustrated in Figure 1 .
  • the immobilized hairpin 10 has regions B and D which are mutually complementary and form an intramolecular duplex (also referred to herein as a "stem").
  • the region A of hairpin 10 forms a pendant single-strand, and is preferably selected to be, at least in part, substantially complementary to a target nucleic acid sequence.
  • the linker C of hairpin 10 is a member which covalently or non-covalently links the nucleic acid sequences B and D together and positions them (e.g., holds them in sufficiently close proximity) such that a B:D intramolecular duplex can form.
  • Figure 1 illustratively shows the hairpin 10 immobilized to an insoluble support 15 through a spacer moiety 12.
  • the linker C is also referred to herein as the "loop".
  • C covalently links B and D.
  • C is a nucleic acid sequence, but in other embodiments, C is not a nucleic acid sequence.
  • C is other than a solid or insoluble support. In other preferred embodiments, C is an insoluble support.
  • Figure 1 further shows the hybridization of a target strand 20 to the hairpin capture moiety 10, to form a nicked duplex 25.
  • an optional duplex-binding-ligand binding site 30 is located at the nick in the target:capture moiety duplex, although a duplex-binding-ligand binding site may be absent or may be situated at locations which do not include a nick, as described in more detail below.
  • a hairpin will have at least one single-stranded region contiguous with a region which forms an intramolecular duplex, wherein the single-stranded region is substantially complementary to a target sequence.
  • the nucleic acid sequence A is a single-stranded region which is substantially complementary to a target sequence
  • the nucleic acid sequence B is a region which forms an intramolecular duplex with region D.
  • a "nicked" duplex structure Upon hybridization of the hairpin with a target nucleic acid sequence, a "nicked" duplex structure will be formed, comprising contiguous regions of intramolecular hairpin:hairpin duplex and intermolecular target:hairpin duplex.
  • This arrangement provides several advantages. First, base stacking between the intramolecular duplex and the intermolecular duplex (i.e., between a terminal base of the target sequence and a terminal base of the capture moiety) provides greater sequence stringency than hybridization to a simple single strand, as described in Khrapko et al. (1991) J. DNA Sequencing Mapping 1:375-388 . Second, as detailed below, the nicked duplex structure may include a duplex-binding-ligand binding site.
  • the ability of the capture moiety to hybridize to the correct target sequence will be increased (e.g., the hybridization efficiency is increased), thus increasing the sensitivity of the assay.
  • the use of a unimolecular capture moiety reduces experimental difficulties related to bimolecular moieties. For example, use of a unimolecular capture moiety requires fewer experimental steps than a bimolecular duplex, concentration dependence of duplex formation and stability is eliminated, an intramolecular duplex is more stable than the corresponding intermolecular duplex, and the like.
  • the duplex region of the capture moiety stabilizes (e.g., entropically) the target-specific region of the capture moiety and thereby favors formation of a target:capture moiety duplex.
  • the region D of the capture moiety has a 3' or 5' terminal base; that is, a terminal base which is not linked to the loop region C.
  • the terminal base will be at the 3' or 5' terminus of the region D, depending on the direction of the sequence (e.g., 5'-3' or 3'-5') of the region D.
  • the nucleic acid sequence which ends in a terminal base is referred to herein as a "terminal sequence".
  • the nucleic acid capture moiety is derivatized to allow binding to a solid support.
  • Many methods of derivatizing a nucleic acid for binding to a solid support are known in the art.
  • the capture moiety may be bound to a solid support through covalent or non-covalent bonds.
  • the nucleic acid capture moiety is covalently bound to biotin to form a biotinylated conjugate.
  • the biotinylated conjugate is then bound to a solid surface, for example, by binding to a solid, insoluble support derivatized with avidin or streptavidin.
  • the capture moiety can be conveniently derivatized for binding to a solid support by incorporating modified nucleic acids in the loop region.
  • the capture moiety is derivatized in the loop region to permit binding to a solid support.
  • the capture moiety is derivatized in a region other than the loop or linker region.
  • biotin-modified nucleic acids can be incorporating into the loop region to permit binding to a streptavidin-coated solid support.
  • moieties useful for binding to a solid support e.g., biotin, antibodies, and the like
  • methods for attaching them to nucleic acids are known in the art.
  • an amine-modified nucleic acid base (available from, e.g., Glen Research) can be attached to a solid support (for example, Covalink-NH, a polystyrene surface grafted with secondary amino groups, available from Nunc) through a bifunctional crosslinker (e.g., bis(sulfosuccinimidyl suberate), available from Pierce).
  • a solid support for example, Covalink-NH, a polystyrene surface grafted with secondary amino groups, available from Nunc
  • a bifunctional crosslinker e.g., bis(sulfosuccinimidyl suberate), available from Pierce.
  • a sulfhydryl-functionalized hairpin obtained by treating an amine-functionalized hairpin as described above with Traut's reagent (2-iminothiolane.HCl)
  • a maleimide-coated polystyrene plate available from, e.g., Corning-Costar. Additional spacing moieties can be added to reduce steric hindrance between the capture moiety and the surface of the solid support.
  • exemplary hairpin capture moieties include the two structures: and in which N represents any base, and n is an integer which will generally be between 4 and 50, more preferably between 5 and 30.
  • N represents any base
  • n is an integer which will generally be between 4 and 50, more preferably between 5 and 30.
  • the solid support is a bead, more preferably a magnetic bead.
  • Use of beads allows the derivatized nucleic acid capture moiety to be separated from a reaction mixture by centrifugation or filtration, or, in the case of magnetic beads, by application of a magnetic field.
  • the nucleic acid capture moiety is bound to a surface such as a membrane or a reaction vessel, for example, a 96-well plate.
  • a surface such as a membrane or a reaction vessel, for example, a 96-well plate.
  • use of multi-well plates allows simultaneous screening for multiple target sequences using multiple hairpins, and also allows the use of automated equipment to perform the screening assays.
  • Derivatization of surfaces to allow binding of the capture moiety is conventional in the art. For example, coating of surfaces with streptavidin allows binding of a biotinylated capture moiety. Coating of surfaces with streptavidin has been described in, for example, U.S. Patent No. 5,374,524 to Miller.
  • One method of achieving this result is to synthesize a sufficient amount of the nucleic acid strand corresponding to the constarit region, and then to add on the variable region appropriate for each target sequence by methods known in the art (e.g., chemical synthesis or ligation of a desired sequence).
  • the capture moiety is selected such that upon hybridization with a target nucleic acid sequence, a nicked duplex (e.g., a duplex without gaps) is formed.
  • a nicked duplex e.g., a duplex without gaps
  • the target nucleic acid may be treated with an agent, such as a restriction enzyme, which cleaves the target strand at a known, defined recognition sequence.
  • an agent such as a restriction enzyme
  • the capture moiety and the restriction enzyme can be chosen to provide a nicked duplex upon hybridization of the capture moiety with the selectively cleaved target strand.
  • the target strand may be "tailed" with a specific base or bases to provide a known terminal sequence.
  • the target strand may be modified by chemical (e.g., by phosphoramidite chemistry) or biochemical (e.g., polymerase extension or ligase-catalyzed ligation, when hybridized to a complementary strand) means to provide a known terminal sequence.
  • the capture moiety is selected such that when the target nucleic acid sequence hybridizes to the capture moiety, the target:capture moiety duplex thereby formed contains a binding site for at least one duplex-binding ligand.
  • a duplex-binding ligand is a moiety which binds duplex nucleic acids in preference to single strands.
  • Preferred duplex-binding ligands recognize (bind to) a recognition site (or binding site) of duplex nucleic acid, which is more strongly bound than non-recognition sites, and are referred to herein as "sequence-specific" duplex-binding ligands.
  • the target:capture moiety duplex comprises a binding site for a sequence-specific duplex-binding ligand.
  • the duplex-binding ligand binding site binds a pre-selected duplex-binding ligand.
  • Other preferred duplex-binding ligands do not exhibit site specificity and are referred to herein as "non-sequence-specific" duplex-binding ligands.
  • Exemplary duplex-binding ligands include enzymes, such as restriction enzymes, polymerases, ligases, and the like; drugs such as actinomycin D; non-sequence-specific intercalaters such as ethidium bromide; and the like.
  • the duplex-binding ligand whether sequence-specific or non-sequence-specific, does not covalently modify any duplex, e.g., does not create and/or cleave any covalent bond, e.g., a covalent bond of the capture moiety or the target nucleic acid.
  • the duplex-binding ligand is other than a ligase or a polymerase.
  • the target:capture moiety duplex comprises a binding site for a non-sequence-specific duplex-binding ligand.
  • the capture moiety may be selected such that the terminal base of an intramolecular duplex-forming region, when taken in combination with a terminal base of the target strand, forms a binding site for a duplex-binding ligand.
  • the duplex-binding-ligand binding site includes the nick in the duplex formed by hybridization of the target to the capture moiety.
  • the duplex-binding-ligand Actinomycin D binds preferentially to the sequence 5'-AGCT-3'.
  • the capture moiety may be chosen to have the 5'-terminal sequence 5'-CT- as part of an intramolecular duplex, and the target strand is selected (or modified) to have the 3'-terminale sequence -AG-3'.
  • the nicked duplex 5'-AG-CT-3' is formed, wherein the "G-C" represents the nick between G and C.
  • This embodiment is particularly useful when discrimination between target sequences of differing length (e.g., cut and uncut targets) are used. If the longer target sequence forms an overhang when hybridized to the hairpin capture moiety, addition of a duplex-binding-ligand which has a recognition site which includes the nick site will improve discrimination between cut and uncut target sequences, as described in more detail below and in Examples 1 and 2.
  • the capture moiety can also be selected so that a duplex-binding-ligand binding site will form in a region which does not include an intramolecular duplex (e.g., the duplex-binding-ligand binding site does not include a nick).
  • the duplex-binding ligand binding site does not include any nick.
  • the target sequence may be selected to contain the sequence 5'-AGCT-3'.
  • the target-specific region of the hairpin capture moiety will contain the complementary sequence, and Actinomycin D will recognize the duplex formed upon binding of the target strand to the capture moiety.
  • the presence of the duplex-binding-ligand will increase the amount of target:capture moiety duplex which is formed (by binding the duplex), thereby improving sensitivity.
  • the capture moiety can also be selected so that more than one duplex-binding-ligand binding site is formed upon binding of the target strand to the hairpin.
  • the binding sites may be for a single duplex-binding ligand (for example, several actinomycin D binding sites), or for more than one ligand (e.g., an actinomycin D site and an EcoRI site).
  • duplex denaturing reagents can be used to increase the specificity of target binding to the capture moiety.
  • a duplex denaturant can be used to destabilize duplex formation, particularly duplexes resulting from hybridization of mismatched nucleic acid sequences.
  • Duplex denaturants include any means of favoring single strand formation and disfavoring duplex formation. Increased temperature (heating) may be used as a duplex denaturant, although this is not preferred.
  • a duplex denaturant is a chemical or biochemical reagent.
  • Exemplary duplex denaturants include enzymes and proteins such as single-strand binding protein (e.g., from E.
  • Duplex denaturants can be identified by measuring the Tm of a duplex in the presence and the absence of a suspected duplex denaturant; a duplex denaturant will lower the Tm.
  • Preferred duplex denaturants do not have an adverse effect on other components of a reaction mixture, when used in amounts sufficient to destabilize at least one duplex.
  • a duplex denaturant should not inhibit the activity of enzymes, such as polymerase or ligase, if activity of such enzymes is desired.
  • the duplex-binding ligand is also a duplex-modifying reagent (e.g., a restriction enzyme, a ligase, and the like)
  • a duplex-modifying reagent e.g., a restriction enzyme, a ligase, and the like
  • contacting a target:capture moiety duplex with a duplex modifying agent such as a duplex-selective restriction enzyme can result in selective modification of the duplex, but no modification of the unbound target or unbound capture moiety.
  • the target is detected by detecting modification of the capture moiety or the target sequence.
  • the capture moiety is labelled with a detectable label such as are known in the art, and a target strand is hybridized to the capture moiety.
  • the target:capture moiety intermolecular duplex thus formed is then cleaved by a restriction enzyme. Detection of the labelled fragments of the capture moiety would thereby detect the presence of the target sequence of interest.
  • the methods of the invention are useful in detecting both natural and non-natural nucleic acid sequences.
  • the methods of the invention can be used to detect nucleic acids from the genome of an organism.
  • the methods of the invention can be used to detect the products of nucleic acid reactions such as strand cleavage, ligation, extension, modification, and the like.
  • nucleic acid reactions such as strand cleavage, ligation, extension, modification, and the like.
  • nucleic acid capture moieties to detect the product of ligation of two probes is described.
  • the methods of the invention can be used to detect nucleic acid sequences directly, by hybridization, or indirectly, by detection of amplification products from, for example, polymerase chain reaction or ligase chain reaction.
  • the methods of the invention can discriminate between target sequences differing by only a single base.
  • a single-base mismatch was detected for two of the three possible single base permutations at a particular base of the target.
  • the third permutation did not result in significant discrimination.
  • nearest-neighbor stacking present in the particular sequences used is responsible for this result.
  • use of a hairpin moiety having a different sequence in the stem region will provide adequate discrimination for this target.
  • use of an appropriate sequence should be sufficient to discriminate all possible single base changes in a target sequence (and at any position of the target sequence). If necessary, however, a subsequent experiment can be performed, using a different capture moiety, to resolve any possible ambiguities.
  • the capture moiety is selected for a particular target such that dicrimination of single base mismatches is possible.
  • Detection of target nucleic acid can be by a variety of methods, some of which are known in the art.
  • a labelled secondary probe 50 with a detectable label 52 complementary to a target-complementary region of the capture moiety 10' (which is immobilized on insoluble support 15) can be hybridized to the capture moiety 10' in a reaction mixture.
  • the target nucleic acid is a ligated product 45 formed by ligation of probes 40 and 44 through phosphate 42. A sample suspected of containing the target nucleic acid is then introduced, under conditions such that any target sequence which is present will displace the secondary probe from the capture moiety.
  • the upper reaction scheme of Figure 2 depicts a reaction of a plurality of probes 40 (with phosphate 42) and 44 with a plurality of immobilized capture moieties 10', to which secondary probe 50 is hybridized.
  • the capture moieties 10' are washed to remove unbound probes 40 and 44, and the amount of labelled secondary probe 50 remaining bound to the capture moieties 10' is measured.
  • the probes 44 are not bound to the capture moieties 10' and the secondary probes 50 are not displaced by probes 40.
  • the lower reaction scheme of Figure 2 depicts the reaction of a plurality of ligated products 45 with capture moiety 10'.
  • the methods of the invention can also be used to discriminate between a target strand which has been cleaved (or otherwise modified) and an uncleaved strand, as shown in Figure 3 .
  • the cut strand 48 which has a detectable label 52', is complementary to the capture moiety 10" (which is immobilized on insoluble support 15), while the uncut strand 40', which also has a detectable label 52', has a non-complementary overhang region 55 and is not effectively bound to the capture moiety 10".
  • the target strand can be cut with, for example, a restriction enzyme.
  • a sample is treated with a restriction enzyme and the products are incubated with an appropriately designed capture moiety.
  • the upper panel of Figure 3 illustrates that uncut strand 40' will not be stably bound to the capture moiety 10", as indicated by the equilibrium arrows showing that the hybridization of uncut strands 40' to capture moieties 10" is unfavorable.
  • the equilibrium arrows depict the favored binding of cut strands 48 to capture moieties 10", while the unlabeled fragments 49 are not bound to 10".
  • the optional duplex-binding-ligand binding site 30" is also shown. This scheme allows the methods of the invention to be used for the detection of nucleic acid sequences which do not occur near the terminus of an intact target strand.
  • FIG. 4 Another method of detection is shown in Figure 4 .
  • the capture moiety 10"' (which is immobilized on insoluble support 15) is complementary to a region of only one probe, illustratively probe 44'.
  • a secondary probe 50' (called the detector probe) is labeled with a label moiety 52' and is complementary to a region of the probe 40'.
  • a plurality of unligated probes 44' hybridize to the capture moieties 10"', but are not labelled and so are not detected. Unligated probes 40' are washed away.
  • the ligation product 45' of the probes 40' and 44' is bound to the capture moiety 10"' and the detector probe 50' hybridizes to region 47 of ligation product 45'; thus, only the ligated product is detected.
  • the optional duplex-binding-ligand binding site 30'" is also shown.
  • target nucleic acids with the capture moieties of the invention are possible.
  • the target nucleic acid can be amplified before or after hybridization with the capture moiety to improve sensitivity.
  • labels are useful for detecting binding of target nucleic acids to capture moieties according to the present invention.
  • radioisotopes for example, 32 P
  • fluorescent labels for example, fluorescent labels
  • enzymes such as alkaline phosphatase and horseradish peroxidase, which can be used in colorimetric methods
  • antibodies chemiluminescence, bioluminescence, and the like.
  • a colorimetric method is used to detect target strand binding to a capture moiety.
  • labels can be attached to the capture moiety, the target nucleic acid, or a secondary probe, according to the desired method of detection.
  • binding of a target strand to a capture moiety can be detected by chromatographic or electrophoretic methods, although this not preferred.
  • the methods of the invention are easily performed manually, they are readily adapted to use with automated equipment.
  • robotic workstations are available which are capable of performing multiple analyses in parallel through the use of automated pipetting and automated plate readers for use with multi-well plates (described in more detail in Example 5, infra ).
  • the methods of the invention are performed with automated equipment.
  • the use of automated equipment allows rapid, inexpensive analysis of single or multiple samples, for one or more target nucleic acid sequences.
  • the reaction mixture includes one or more of the following: an immobilized hairpin, a solid or insoluble support, a non-immobilized hairpin, a target nucleic acid strand, a sequence-specific duplex-binding ligand, a non-sequence-specific duplex-binding ligand, a duplex-binding ligand which does not create or cleave any covalent bond, a duplex denaturant a standard.
  • the reaction mixture can be a solution.
  • kits for the detection of a target nucleic acid includes one or more of the following: an immobilized hairpin, a non-immobilized hairpin, a solid or insoluble support, a standard, a sequence-specific duplex-binding ligand, a non-sequence-specific duplex-binding ligand, a duplex-binding ligand which does not create or cleave any covalent bond, a duplex denaturant, instructions for use.
  • standard refers to a nucleic acid strand which is pre-selected to be substantially complementary to a single-stranded region of a capture moiety.
  • the immobilized nucleic acid hairpin was provided in the following manner: 1 mg of prewashed streptavidin-coated magnetic beads (available from Dynal) in 200 ⁇ l of BN buffer (1M NaCl/1mM EDTA/ 0.025% Triton-X 100/ 10mM Tris HCl, pH 7.5) was incubated with 500 pmol of the biotinylated hairpin (synthesized on an DNA synthesizer; the biotinylated bases were obtained from Glen Research) for one hour at room temperature with gentle rotation.
  • the biotinylated hairpin had the following structure: The hairpin and probe were chosen so that hybridization of the complementary probe with the hairpin forms a binding site for the duplex-binding ligand Actinomycin D (e.g., 5'-AGCT-3'). The beads were then washed three times with BN buffer to remove unattached hairpin. Separate experiments with radiolabelled biotinylated hairpin established that about 20% (200 pmol) of the hairpin was bound to the beads.
  • Actinomycin D e.g., 5'-AGCT-3'
  • the 13-mer Probe 1 (SEQ ID NO. 3), the 17-mer Probe 2 (SEQ ID NO. 4), and the hairpin capture moiety were prepared as in Example 1.
  • the non-complementary 20-mer 5'-TTATA ATTAA CCGGT ATATA-3' (SEQ ID NO. 6) was also synthesized by standard methods on an automated DNA synthesizer. Binding experiments were performed as described above, except that the beads were washed with 3 wash buffers contained decreasing salt concentrations; the first wash buffer had 1M NaCl, the second wash was with 0.1M NaCl, and the third wash was with 0.01M NaCl. None of the wash buffers contained urea or Actinomycin D.
  • the hairpin capture moiety used in Example 1 was incubated with one of three oligonucleotides: the 13-mer complementary strand (SEQ ID NO. 3), a 22-mer complementary strand 5'-GGCGT TAACC AGCGC GTTTT AG-3' (SEQ ID NO. 7), and a non-complementary 26-mer strand 5'-TACCG GAAGG AATTC TTCGT GCATG A-3' (SEQ ID NO. 8).
  • the experiments were performed as described in Example 1. The probes were tested at several copy numbers. The results are shown in Figure 7 .
  • the target sequence was a 32-mer 5'-ATTTT TTGCA AATTT TTATT TGCCC GAGTA TA-3' (SEQ ID NO. 9) which corresponds to the E. coli rhsA gene.
  • the two probes complementary to the product, probe 1 (17-mer) and probe 2 (15-mer), are shown below.
  • Probe 1 5'-TTATT TGCCC GAGTA TA-3' SEQ ID NO. 10
  • Probe 2 5'-ATTTT TTGCA AATTT-3' SEQ ID NO. 11
  • Probe 1 was 5'-phosphorylated with 32 P following a standard kinasing protocol.
  • the ligation reactions were performed in a microcentrifuge tube with 0.1 nmol Probe 2 and 20,000 CPM Probe 1 (about 1 fmol) in buffer (50mM Tris-HCl, pH 7.8, 10mM MgCl 2 , 10mM dithiothreitol, 25 ug/ml bovine serum albumin, 1 mM ATP), total volume 20 ⁇ l.
  • the target concentration was varied from 0.1 ⁇ M to 1 fM in 10-fold steps.
  • Samples were annealed by heating to 90° for 5 minutes, and then cooled to room temperature. T4 ligase (400 units) was added (except to the no enzyme control) and the samples incubated at 37° for 2-4 hours. The ligase was inactivated by heating to 90° for 5 minutes.
  • the beads had a total of about 4 pmol of immobilized hairpin capture moiety.
  • the samples were incubated for 20-30 minutes at room temperature with gentle rotation, and then were separated from the buffer with a magnet and washed three times with BN buffer. The products were then separated by polyacrylamide gel electrophoresis. Films were exposed for 24 hours. Control samples which were not treated with the hairpin capture moiety were also analyzed.
  • the results are shown in Figures 8 and 9 .
  • the bottom panel of Figure 8 shows the band pattern of the reaction mixture before treatment with the hairpin capture moiety (control mixture).
  • the lower band is unreacted probe; the main upper band is the ligated product.
  • the small band at high copy numbers is an artifact.
  • Ligated product is visible at 10 4 copies of target.
  • the upper panel of Figure 8 shows the band pattern of the reaction products bound to the capture moiety. Very little unligated probe is seen, demonstrating the high selectivity of the system for the ligated product.
  • the sensitivity of the system is almost the same as in the control mixture (lower panel), namely about 10 4 -10 5 copies of target (the grainy pattern seen in several lanes of the upper panel is an unrelated artifact). Note that at high target copy number the amount of ligated product captured by the hairpin decreases; this is believed to be due to the presence of excess target, which competes for the ligated product.
  • Figure 9 shows a similar experiment performed with 800 units of T4 ligase. The results are similar to Figure 8 .
  • the lane labelled “10 9 " in the lower panel resulted from a flawed experiment.
  • This Example describes the use of multi-well plates for automated screening of samples for multiple target nucleic acid sequences.
  • Biotinylated DNA hairpins are synthesized according to the methods described in Example 1.
  • One DNA hairpin sequence is synthesized for each target sequence of interest. For example, in screening for cystic fibrosis, several sequences which correspond to different mutations and are diagnostic for the disease would be used.
  • Each well of a 96-well plate is coated with streptavidin as described in, for example, U.S. Patent No. 5,374,524 to Miller , and a plurality of biotinylated hairpins of one sequence are immobilized in each well. Unbound hairpins are removed by washing with buffer, and the prepared 96-well plate is placed in a robotic workstation. The workstation is programmed to add 100 ⁇ l of buffer to each well.
  • the buffer contains urea (5M) and Actinomycin D (400 ⁇ M). Addition of buffer is followed by addition of 10 ⁇ l of a solution of sample DNA.
  • the 96-well plate is incubated at room temperature for one hour, and the reaction mixture is then removed from each well by automated pipet.
  • the wells are rinsed three times with buffer to remove unbound DNA. Then a solution containing a secondary probe, which is complementary to a region of the target sequence and has been labelled by covalent attachment of alkaline phosphatase according to well-known techniques, is added. The samples are again incubated, and the unhybridized probe is removed. The wells are rinsed with buffer and then treated with a solution of BCIP (5-bromo-4-chloro-3-indolylphosphate) and NBT (nitroblue tetrazolium). Wells having hairpins which bound to the sample DNA will develop a blue color which can be read by a conventional plate reader.
  • BCIP 5-bromo-4-chloro-3-indolylphosphate
  • NBT nitrogen blue tetrazolium
  • This assay is rapid, specific, uses standard equipment, and can easily be modified to detect any desired target nucleic acid.
  • Example 1 The immobilized hairpin of Example 1 (SEQ ID NO. 5) was used to capture the matched probe of Example 1 (SEQ ID NO. 3) and mismatched probes identical to the matched probe except that the 3'- terminal base was either C, A, or T, as shown in Figure 10 .
  • the experimental conditions were as set out in Example 1. The results are shown in Figure 11 , which depicts the fraction of melted duplex as a function of temperature.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)

Abstract

Nucleic acid capture moieties, methods of using nucleic acid capture moieties, reaction mixtures including nucleic acid capture moieties, and kits including nucleic acid capture moieties are disclosed.

Description

    Background of the Invention
  • The present invention pertains to methods of detecting nucleic acid sequences.
  • Methods of detecting sequences of nucleic acids are of wide applicability in fields such as medical diagnosis.
  • In one prior art method, described, for example, in US patent 4,358,535 to Falkow , the target nucleic acid is immobilised on a solid surface, such as nitrocellulose filter. The target is then detected by hybridization with a labelled probe which is complementary to the target.
    Other methods include those assays generally described as "sandwich assays", such as those disclosed by Dunn et al., Cell 12:33-36 (1977); and US Patent 4,563,419 to Ranki. In this format, a target nucleic acid is hybridized to a capture probe, and a second, reporter probe complementary to the target but not to the capture probe, is then added. Excess probes are washed away and binding of the reporter probe is measured. A solution sandwich assay is described in US Patent 5,374,524 to Miller. Broude et al. (Proc. Natl. Acad. Sci. USA 91:3072 (1994)) have reported a nucleic acid capture system which uses an immobilised probe having single-stranded and duplex regions. This system was found to have increased sequence specificity compared to simple single-stranded probes.
    US Patent 5215899 (Miles Inc.) discloses specific nucleic acid sequences being amplified through the use of a hairpin probe which, upon hybridization with and ligation to, a target sequence is capable of being transcribed. However, a duplex-binding ligand is not used in any part of reaction mixtures therein.
    Carpenter W.R. et al. disclose [Clin. Chem. (1993), 39/9 1934-1938] a transcriptionally amplified DNA probe assay with ligatable probes and immunochemical detection. However, again, no duplex-binding ligand is present in any part of the reaction mixtures employed.
  • Summary of the Invention
  • The methods of the invention feature nucleic acid capture moieties which are complementary to a target sequence to sensitively and selectively detect target nucleic acid sequences.
  • According to the present invention there are provided methods as set out in the appended claims.
  • In one aspect, the invention features a method of capturing a target single-stranded nucleic acid sequence on a solid support, the method comprising the steps of:
    1. (a) providing a nucleic acid capture moiety immobilized on the solid support, the nucleic acid capture moiety comprising a structure A-B-C-D wherein
      A is a nucleic acid sequence;
      B and D are nucleic acid sequences which are capable of hybridizing to each other to form an intramolecular duplex; and
      C is a linker; which covalently links B and D;
      wherein A is complementary to the target single-stranded nucleic acid sequence;
    2. (b) forming a reaction mixture comprising said target single-stranded nucleic acid and said nucleic acid capture moiety under conditions such that the target single-stranded nucleic acid and the nucleic acid capture moiety can hybridize to form an intermolecular duplex; and
    3. (c) capturing the target single-stranded nucleic acid on the solid support by hybridizing the target single-stranded nucleic acid to said immobilized nucleic acid capture moiety to separate the target single-stranded nucleic acid hybridized to the nucleic acid capture moiety from the reaction mixture, wherein stability of the intermolecular duplex is increased by base stacking between a terminal base of the nucleic acid capture moiety and a terminal base of the target single-stranded nucleic acid which forms a part of the intermolecular duplex.
  • In a preferred embodiment, the method further comprises the step of detecting the presence or absence of hybridization of the target nucleic acid and the nucleic acid capture moiety, such that the target single-stranded nucleic acid is detected.
  • In preferred embodiments, the intermolecular duplex comprises a duplex-binding-ligand binding site; hybridization of the target single-stranded nucleic acid to the nucleic acid capture moiety forms a nicked duplex; the duplex-binding-ligand binding site does not include a nick; the reaction mixture further comprises a duplex-binding ligand; the duplex-binding ligand is sequence-specific; the duplex-binding ligand does not covalently modify any duplex.
  • Also described herein is a reaction mixture for promoting hybridization of a nucleic acid hairpin and a target nucleic acid comprising:
    • an immobilised nucleic acid capture moiety comprising a structure A-B-C-D wherein;
      A is a nucleic acid sequence;
      B and D are nucleic acid sequences which are capable of hybridizing to each other to form an intramolecular duplex; and
      C is a linker; which covalently links B and D;
    • an insoluble support; and
    • a target nucleic acid;
    wherein A is complementary to the target nucleic acid;
    wherein the hairpin is selected such that hybridization of the hairpin and the target nucleic acid forms an intermolecular duplex comprising a duplex-binding-ligand binding site whereby binding of a duplex-binding ligand to the duplex-binding-ligand binding site promotes hybridization of the target nucleic acid and the nucleic acid capture moiety,
    wherein stability of the intermolecular duplex is increased by base stacking between a terminal base of the nucleic acid capture moiety and a terminal base of the target single-stranded nucleic acid which forms part of the intermolecular duplex. Brief Description of the Drawings
    • Figure 1 is a reaction scheme showing capture of a target nucleic acid by a nucleic acid hairpin.
    • Figure 2 is a reaction scheme showing detection of a target nucleic acid by displacement of a labelled secondary probe from a capture moiety.
    • Figure 3 is a reaction scheme showing discrimination between a cut target and an uncut target nucleic acid.
    • Figure 4 is a reaction scheme showing detection of a ligated target nucleic acid by hybridization of a target-complementary secondary probe.
    • Figure 5 is a bar graph showing the binding efficiency of cut and uncut target nucleic acid in varying conditions.
    • Figure 6 is a bar graph showing effects of wash buffer salt concentration on binding efficiency.
    • Figure 7 is a bar graph showing the effect of target copy number on binding efficiency.
    • Figure 8 is a gel showing the detection of ligated products by a hairpin capture moiety.
    • Figure 9 is another gel showing the detection of ligated products by a hairpin capture moiety.
    • Figure 10 shows a capture moiety and matched and mismatched target sequences.
    • Figure 11 is a graph depicting the melting temperatures of matched and mismatched target nucleic acids hybridized to a nucleic acid capture moiety.
    Detailed Description
  • The methods of the invention are useful in the detection of nucleic acid sequences. The invention features nucleic acid capture moieties for use in detecting target nucleic acids. The methods of the invention can be performed with capture moieties immobilized in multiwell plates; thus, multiple samples can be screened simultaneously. Also, the methods of the invention can easily be automated, at least in part, to speed screening and improve economy. The capture moieties can selectively bind the target sequence, thereby reducing background noise to very low levels. An additional advantage is that the label signal can be amplified to achieve highly sensitive detection.
  • The term "nucleic acid strand", as used herein, refers to a strand of DNA or RNA, or a chimeric DNA-RNA strand, or nucleic acid-like compounds such as peptide nucleic acids. A nucleic acid strand can also include modified DNA or RNA bases, of which many are known in the art.
  • The term "target nucleic acid sequence" or "target strand" refers to a nucleic acid sequence which is to be detected. The target nucleic acid sequence can be any nucleic acid strand, as defined above, and in general will be single-stranded or will be made single-stranded by methods known in the art. The target nucleic acid sequence can be obtained from various sources including plasmids, viruses, bacteria, fungi, yeast, plants, and animals, including humans; or the target nucleic acid sequence can be obtained from non-natural sources. The target nucleic acid sequence can be obtained from various organisms or tissues, including fluids such as blood, semen, urine and the like. The target nucleic acid sequence is preferably extracted or purified to remove or reduce contaminating or interfering materials such as proteins or cellular debris. Procedures for such purification or extraction are known in the art, including, for example, those described in Maniatis et al., "Molecular Cloning: A Laboratory Manual", Cold Spring Harbor Laboratory (1989), or in Bell et al., Proc. Nat. Acad. Sci. USA (1981), 78:5759-5763. The methods of the present invention are particularly useful in the detection of nucleic acid sequences associated with infectious diseases, genetic disorders, or cellular conditions such as cancer. The methods of the invention are also useful for the detection of non-natural target nucleic acids, as described in more detail below.
  • The term "adjacent", as used herein, refers to non-overlapping segments of a nucleic acid strand which are not separated by intervening bases.
  • Described is a nucleic acid capture moiety which has at least one nucleic acid region which is substantially complementary to a target nucleic acid, and having at least two nucleic acid regions which are capable of forming an intramolecular duplex. The term "nucleic acid capture moiety" or simply "capture moiety", as used herein, refers to a moiety which binds selectively to a target nucleic acid sequence and which can be immobilized on an insoluble support. The capture moiety can be immobilized on the solid support before, simultaneous with, or after capturing the target strand. A capture moiety can "capture" a target nucleic acid by hybridizing to the target and thereby immobilizing the target. The nucleic acid capture moiety comprises a nucleic acid strand which has at least one region which is substantially complementary to a region of the target nucleic acid sequence, and forms a nucleic acid hairpin, as defined below. In general, a capture moiety will be bound to a solid support. Such binding to a solid support may be through a linking moiety which is bound to either the capture moiety or to the solid support. In certain embodiments, the capture moiety may be labelled, as with, e.g., a radioisotope, a fluorescent moiety, an antibody, an antigen, a lectin, an enzyme, or other labels well known in the art. In embodiments in which the capture moiety does not contain a detectable label, the target nucleic acid sequence may be so labelled, or, alternatively, labelled secondary probes may be employed. A "secondary probe" is a nucleic acid sequence which is complementary to either a region of the target nucleic acid sequence or to a region of the capture moiety.
  • The terms "nucleic acid hairpin", "hairpin capture moiety", or simply "hairpin", as used herein, refer to a unimolecular nucleic acid-containing structure which comprises at least two mutually complementary nucleic acid regions such that at least one intramolecular duplex can form. Hairpins are described in, for example, Cantor and Schimmel, "Biophysical Chemistry", Part III, p. 1183 (1980). In certain embodiments, the mutually complementary nucleic acid regions are connected through a nucleic acid strand; in these embodiments, the hairpin comprises a single strand of nucleic acid. A region of the capture moiety which connects regions of mutual complementarity is referred to herein as a "loop" or "linker". In preferred embodiments, a loop comprises a strand of nucleic acid or modified nucleic acid. In preferred embodiments, the linker is not a hydrogen bond. In other embodiments, the loop comprises a linker region which is not nucleic-acid-based; however, capture moieties in which the loop region is not a nucleic acid sequence are referred to herein as hairpins. Examples of non-nucleic-acid linkers suitable for use in the loop region are known in the art and include, for example, alkyl chains (see, e.g., Doktycz et al. (1993) Biopolymers 33:1765). While it will be understood that a loop can be a single-stranded region of a hairpin, for the purposes of the discussion below, a "single-stranded region" of a hairpin refers to a non-loop region of a hairpin. In embodiments in which the loop is a nucleic acid strand, the loop preferably comprises 2-20 nucleotides, more preferably 3-8 nucleotides. The size or configuration of the loop or linker is selected to allow the regions of mutual complementarity to form an intramolecular duplex. In preferred embodiments, hairpins useful in the present invention will form at least one intramolecular duplex having at least 2 base pairs, more preferably at least 4 base pairs, and still more preferably at least 8 base pairs. The number of base pairs in the duplex region, and the base composition thereof, can be chosen to assure any desired relative stability of duplex formation. For example, to prevent hybridization of non-target nucleic acids with the intramolecular duplex-forming regions of the hairpin, the number of base pairs in the intramolecular duplex region will generally be greater than about 4 base pairs. The hairpin described in Example 3, infra, has a 16-base-pair duplex region, conferring exceptional stability on the intramolecular duplex. The intramolecular duplex will generally not have more than about 40 base pairs. In preferred embodiments, the intramolecular duplex is less than 30 base pairs, more preferably less than 20 base pairs in length.
  • A hairpin may be capable of forming more than one loop. For example, a hairpin capable of forming two intramolecular duplexes and two loops is referred to herein as a "double hairpin". In preferred embodiments, a hairpin will have at least one single-stranded region which is substantially complementary to a target nucleic acid sequence. "Substantially complementary" means capable of hybridizing to a target nucleic acid sequence under the conditions employed. In preferred embodiments, a "substantially complementary" single-stranded region is exactly complementary to a target nucleic acid sequence. In preferred embodiments, hairpins useful in the present invention have a target-complementary single-stranded region having at least 5 bases, more preferably at least 8 bases. In preferred embodiments, the hairpin has a target-complementary single-stranded region having fewer than 30 bases, more preferably fewer than 25 bases. The target-complementary region will be selected to ensure that target strands form stable duplexes with the capture moiety. In embodiments in which the capture moiety is used to detect target strands from a large number of non-target sequences (e.g., when screening genomic DNA), the target-complementary region should be sufficiently long to prevent binding of non-target sequences. A target-specific single-stranded region may be at either the 3' or the 5' end of the capture moiety strand, or it may be situated between two intramolecular duplex regions (for example, between two duplexes in a double hairpin).
  • Hairpins useful in the present invention have the structure A-B-C-D
    wherein
    A is a target-specific nucleic acid sequence;
    B and D are nucleic acid sequences which are capable of hybridizing to each other to form an intramolecular duplex; and
    C is a linker.
  • Thus, immobilized hairpins have the general structure illustrated in Figure 1. The immobilized hairpin 10 has regions B and D which are mutually complementary and form an intramolecular duplex (also referred to herein as a "stem"). The region A of hairpin 10 forms a pendant single-strand, and is preferably selected to be, at least in part, substantially complementary to a target nucleic acid sequence. The linker C of hairpin 10 is a member which covalently or non-covalently links the nucleic acid sequences B and D together and positions them (e.g., holds them in sufficiently close proximity) such that a B:D intramolecular duplex can form. Figure 1 illustratively shows the hairpin 10 immobilized to an insoluble support 15 through a spacer moiety 12. The linker C is also referred to herein as the "loop". In preferred embodiments, C covalently links B and D. In preferred embodiments, C is a nucleic acid sequence, but in other embodiments, C is not a nucleic acid sequence. In preferred embodiments, C is other than a solid or insoluble support. In other preferred embodiments, C is an insoluble support. Figure 1 further shows the hybridization of a target strand 20 to the hairpin capture moiety 10, to form a nicked duplex 25. In Figure 1, an optional duplex-binding-ligand binding site 30 is located at the nick in the target:capture moiety duplex, although a duplex-binding-ligand binding site may be absent or may be situated at locations which do not include a nick, as described in more detail below.
  • In particularly preferred embodiments, a hairpin will have at least one single-stranded region contiguous with a region which forms an intramolecular duplex, wherein the single-stranded region is substantially complementary to a target sequence. In an illustrative embodiment, the nucleic acid sequence A is a single-stranded region which is substantially complementary to a target sequence, and the nucleic acid sequence B is a region which forms an intramolecular duplex with region D.
  • Upon hybridization of the hairpin with a target nucleic acid sequence, a "nicked" duplex structure will be formed, comprising contiguous regions of intramolecular hairpin:hairpin duplex and intermolecular target:hairpin duplex. This arrangement provides several advantages. First, base stacking between the intramolecular duplex and the intermolecular duplex (i.e., between a terminal base of the target sequence and a terminal base of the capture moiety) provides greater sequence stringency than hybridization to a simple single strand, as described in Khrapko et al. (1991) J. DNA Sequencing Mapping 1:375-388. Second, as detailed below, the nicked duplex structure may include a duplex-binding-ligand binding site. In the presence of an appropriate duplex-binding ligand, the ability of the capture moiety to hybridize to the correct target sequence will be increased (e.g., the hybridization efficiency is increased), thus increasing the sensitivity of the assay. Furthermore, the use of a unimolecular capture moiety reduces experimental difficulties related to bimolecular moieties. For example, use of a unimolecular capture moiety requires fewer experimental steps than a bimolecular duplex, concentration dependence of duplex formation and stability is eliminated, an intramolecular duplex is more stable than the corresponding intermolecular duplex, and the like. Also, the duplex region of the capture moiety stabilizes (e.g., entropically) the target-specific region of the capture moiety and thereby favors formation of a target:capture moiety duplex. In a preferred embodiment, the region D of the capture moiety has a 3' or 5' terminal base; that is, a terminal base which is not linked to the loop region C. The terminal base will be at the 3' or 5' terminus of the region D, depending on the direction of the sequence (e.g., 5'-3' or 3'-5') of the region D. The nucleic acid sequence which ends in a terminal base is referred to herein as a "terminal sequence".
  • In preferred embodiments, the nucleic acid capture moiety is derivatized to allow binding to a solid support. Many methods of derivatizing a nucleic acid for binding to a solid support are known in the art. The capture moiety may be bound to a solid support through covalent or non-covalent bonds. In a preferred embodiment, the nucleic acid capture moiety is covalently bound to biotin to form a biotinylated conjugate. The biotinylated conjugate is then bound to a solid surface, for example, by binding to a solid, insoluble support derivatized with avidin or streptavidin. The capture moiety can be conveniently derivatized for binding to a solid support by incorporating modified nucleic acids in the loop region. Thus, in a preferred embodiment, the capture moiety is derivatized in the loop region to permit binding to a solid support. In other preferred embodiments, the capture moiety is derivatized in a region other than the loop or linker region. For example, biotin-modified nucleic acids can be incorporating into the loop region to permit binding to a streptavidin-coated solid support. As noted above, a variety of moieties useful for binding to a solid support (e.g., biotin, antibodies, and the like), and methods for attaching them to nucleic acids, are known in the art. For example, an amine-modified nucleic acid base (available from, e.g., Glen Research) can be attached to a solid support (for example, Covalink-NH, a polystyrene surface grafted with secondary amino groups, available from Nunc) through a bifunctional crosslinker (e.g., bis(sulfosuccinimidyl suberate), available from Pierce). In another example, a sulfhydryl-functionalized hairpin (obtained by treating an amine-functionalized hairpin as described above with Traut's reagent (2-iminothiolane.HCl)) can be attached to a maleimide-coated polystyrene plate, available from, e.g., Corning-Costar. Additional spacing moieties can be added to reduce steric hindrance between the capture moiety and the surface of the solid support.
  • Thus, exemplary hairpin capture moieties include the two structures:
    Figure imgb0001
    and
    Figure imgb0002
    in which N represents any base, and n is an integer which will generally be between 4 and 50, more preferably between 5 and 30. These illustrative hairpins have been derivatized, with biotin, in the loop region for binding to a solid support, although such is not required.
  • In preferred embodiments, the solid support is a bead, more preferably a magnetic bead. Use of beads allows the derivatized nucleic acid capture moiety to be separated from a reaction mixture by centrifugation or filtration, or, in the case of magnetic beads, by application of a magnetic field. In other preferred embodiments, the nucleic acid capture moiety is bound to a surface such as a membrane or a reaction vessel, for example, a 96-well plate. As discussed more fully below, use of multi-well plates allows simultaneous screening for multiple target sequences using multiple hairpins, and also allows the use of automated equipment to perform the screening assays. Derivatization of surfaces to allow binding of the capture moiety is conventional in the art. For example, coating of surfaces with streptavidin allows binding of a biotinylated capture moiety. Coating of surfaces with streptavidin has been described in, for example, U.S. Patent No. 5,374,524 to Miller.
  • In certain embodiments, it may be desired to use a plurality of hairpin sequences to detect a plurality of target sequences. In such embodiments, it is advantageous, although not required, to synthesize the hairpins with a constant region, which is the same for each hairpin and includes the loop and intramolecular duplex-forming regions, and a variable, target-specific region, which differs from one hairpin to the next according to the desired target sequence. One method of achieving this result is to synthesize a sufficient amount of the nucleic acid strand corresponding to the constarit region, and then to add on the variable region appropriate for each target sequence by methods known in the art (e.g., chemical synthesis or ligation of a desired sequence).
  • The capture moiety is selected such that upon hybridization with a target nucleic acid sequence, a nicked duplex (e.g., a duplex without gaps) is formed. This result may be achieved in various ways. For example, before contacting the target nucleic acid sequence with the capture moiety, the target nucleic acid may be treated with an agent, such as a restriction enzyme, which cleaves the target strand at a known, defined recognition sequence. Thus, the target nucleic acid sequence after cleavage will terminate with a known base or bases. The capture moiety and the restriction enzyme can be chosen to provide a nicked duplex upon hybridization of the capture moiety with the selectively cleaved target strand. Alternatively, the target strand may be "tailed" with a specific base or bases to provide a known terminal sequence. For example, the target strand may be modified by chemical (e.g., by phosphoramidite chemistry) or biochemical (e.g., polymerase extension or ligase-catalyzed ligation, when hybridized to a complementary strand) means to provide a known terminal sequence.
  • In preferred embodiments, the capture moiety is selected such that when the target nucleic acid sequence hybridizes to the capture moiety, the target:capture moiety duplex thereby formed contains a binding site for at least one duplex-binding ligand. A duplex-binding ligand is a moiety which binds duplex nucleic acids in preference to single strands. Preferred duplex-binding ligands recognize (bind to) a recognition site (or binding site) of duplex nucleic acid, which is more strongly bound than non-recognition sites, and are referred to herein as "sequence-specific" duplex-binding ligands. Thus, in a preferred embodiment, the target:capture moiety duplex comprises a binding site for a sequence-specific duplex-binding ligand. In preferred embodiments, the duplex-binding ligand binding site binds a pre-selected duplex-binding ligand. Other preferred duplex-binding ligands do not exhibit site specificity and are referred to herein as "non-sequence-specific" duplex-binding ligands. Exemplary duplex-binding ligands include enzymes, such as restriction enzymes, polymerases, ligases, and the like; drugs such as actinomycin D; non-sequence-specific intercalaters such as ethidium bromide; and the like. In preferred embodiments, the duplex-binding ligand, whether sequence-specific or non-sequence-specific, does not covalently modify any duplex, e.g., does not create and/or cleave any covalent bond, e.g., a covalent bond of the capture moiety or the target nucleic acid. In preferred embodiments, the duplex-binding ligand is other than a ligase or a polymerase.
  • In other preferred embodiments, the target:capture moiety duplex comprises a binding site for a non-sequence-specific duplex-binding ligand.
  • The capture moiety may be selected such that the terminal base of an intramolecular duplex-forming region, when taken in combination with a terminal base of the target strand, forms a binding site for a duplex-binding ligand. In other words, the duplex-binding-ligand binding site includes the nick in the duplex formed by hybridization of the target to the capture moiety. For example, the duplex-binding-ligand Actinomycin D binds preferentially to the sequence 5'-AGCT-3'. Illustratively, the capture moiety may be chosen to have the 5'-terminal sequence 5'-CT- as part of an intramolecular duplex, and the target strand is selected (or modified) to have the 3'-terminale sequence -AG-3'. Thus, upon hybridization of the target strand to the capture moiety, the nicked duplex 5'-AG-CT-3' is formed, wherein the "G-C" represents the nick between G and C. This embodiment is particularly useful when discrimination between target sequences of differing length (e.g., cut and uncut targets) are used. If the longer target sequence forms an overhang when hybridized to the hairpin capture moiety, addition of a duplex-binding-ligand which has a recognition site which includes the nick site will improve discrimination between cut and uncut target sequences, as described in more detail below and in Examples 1 and 2.
  • The capture moiety can also be selected so that a duplex-binding-ligand binding site will form in a region which does not include an intramolecular duplex (e.g., the duplex-binding-ligand binding site does not include a nick). In preferred embodiments, the duplex-binding ligand binding site does not include any nick. For example, the target sequence may be selected to contain the sequence 5'-AGCT-3'. Thus, the target-specific region of the hairpin capture moiety will contain the complementary sequence, and Actinomycin D will recognize the duplex formed upon binding of the target strand to the capture moiety. The presence of the duplex-binding-ligand will increase the amount of target:capture moiety duplex which is formed (by binding the duplex), thereby improving sensitivity.
  • The capture moiety can also be selected so that more than one duplex-binding-ligand binding site is formed upon binding of the target strand to the hairpin. The binding sites may be for a single duplex-binding ligand (for example, several actinomycin D binding sites), or for more than one ligand (e.g., an actinomycin D site and an EcoRI site). By adding the appropriate duplex-binding ligands, a desirable balance between detection sensitivity and target selectivity can be obtained.
  • It will also be recognized that duplex denaturing reagents can be used to increase the specificity of target binding to the capture moiety. In other words, a duplex denaturant can be used to destabilize duplex formation, particularly duplexes resulting from hybridization of mismatched nucleic acid sequences. Duplex denaturants include any means of favoring single strand formation and disfavoring duplex formation. Increased temperature (heating) may be used as a duplex denaturant, although this is not preferred. In preferred embodiments, a duplex denaturant is a chemical or biochemical reagent. Exemplary duplex denaturants include enzymes and proteins such as single-strand binding protein (e.g., from E. coli), the G-5 protein, the gene 32 protein, Rec A, and helicases, as well as chemical denaturants such as urea. Duplex denaturants can be identified by measuring the Tm of a duplex in the presence and the absence of a suspected duplex denaturant; a duplex denaturant will lower the Tm. Preferred duplex denaturants do not have an adverse effect on other components of a reaction mixture, when used in amounts sufficient to destabilize at least one duplex. For example, a duplex denaturant should not inhibit the activity of enzymes, such as polymerase or ligase, if activity of such enzymes is desired.
  • If the duplex-binding ligand is also a duplex-modifying reagent (e.g., a restriction enzyme, a ligase, and the like) other methods of detection are possible. For example, contacting a target:capture moiety duplex with a duplex modifying agent such as a duplex-selective restriction enzyme can result in selective modification of the duplex, but no modification of the unbound target or unbound capture moiety. With an appropriate choice of target and capture moiety, the target is detected by detecting modification of the capture moiety or the target sequence. In an exemplary embodiment, the capture moiety is labelled with a detectable label such as are known in the art, and a target strand is hybridized to the capture moiety. The target:capture moiety intermolecular duplex thus formed is then cleaved by a restriction enzyme. Detection of the labelled fragments of the capture moiety would thereby detect the presence of the target sequence of interest.
  • The methods of the invention are useful in detecting both natural and non-natural nucleic acid sequences. For example, the methods of the invention can be used to detect nucleic acids from the genome of an organism. In other embodiments, the methods of the invention can be used to detect the products of nucleic acid reactions such as strand cleavage, ligation, extension, modification, and the like. For example, in Example 3, infra, the use of nucleic acid capture moieties to detect the product of ligation of two probes is described. Thus, the methods of the invention can be used to detect nucleic acid sequences directly, by hybridization, or indirectly, by detection of amplification products from, for example, polymerase chain reaction or ligase chain reaction.
  • As described below in Example 6, the methods of the invention can discriminate between target sequences differing by only a single base. In the experiment described in Example 6, a single-base mismatch was detected for two of the three possible single base permutations at a particular base of the target. The third permutation did not result in significant discrimination. Without wishing to be bound by theory, it is believed that nearest-neighbor stacking present in the particular sequences used is responsible for this result. Accordingly, it is believed that use of a hairpin moiety having a different sequence in the stem region will provide adequate discrimination for this target. Furthermore, use of an appropriate sequence should be sufficient to discriminate all possible single base changes in a target sequence (and at any position of the target sequence). If necessary, however, a subsequent experiment can be performed, using a different capture moiety, to resolve any possible ambiguities. In preferred embodiments, the capture moiety is selected for a particular target such that dicrimination of single base mismatches is possible.
  • Detection of target nucleic acid can be by a variety of methods, some of which are known in the art. In an illustrative embodiment, as shown in Figure 2, a labelled secondary probe 50 with a detectable label 52 complementary to a target-complementary region of the capture moiety 10' (which is immobilized on insoluble support 15) can be hybridized to the capture moiety 10' in a reaction mixture. In this illustrative embodiment, the target nucleic acid is a ligated product 45 formed by ligation of probes 40 and 44 through phosphate 42. A sample suspected of containing the target nucleic acid is then introduced, under conditions such that any target sequence which is present will displace the secondary probe from the capture moiety. The upper reaction scheme of Figure 2 depicts a reaction of a plurality of probes 40 (with phosphate 42) and 44 with a plurality of immobilized capture moieties 10', to which secondary probe 50 is hybridized. The capture moieties 10' are washed to remove unbound probes 40 and 44, and the amount of labelled secondary probe 50 remaining bound to the capture moieties 10' is measured. Illustratively, in the upper panel of Figure 2 the probes 44 are not bound to the capture moieties 10' and the secondary probes 50 are not displaced by probes 40. The lower reaction scheme of Figure 2 depicts the reaction of a plurality of ligated products 45 with capture moiety 10'. In the lower reaction scheme of Figure 2, some of the ligated products 45 hybridize to the capture moieties 10', displacing secondary probes 50. A decrease in amount of secondary probe 50 bound to capture moiety 10', compared to a control well, indicates the presence of the target sequence 45. Alternatively, the amount of probe washed off in the washing step can be measured. The optional duplex-binding-ligand binding site 30' is also shown.
  • The methods of the invention can also be used to discriminate between a target strand which has been cleaved (or otherwise modified) and an uncleaved strand, as shown in Figure 3. The cut strand 48, which has a detectable label 52', is complementary to the capture moiety 10" (which is immobilized on insoluble support 15), while the uncut strand 40', which also has a detectable label 52', has a non-complementary overhang region 55 and is not effectively bound to the capture moiety 10". The target strand can be cut with, for example, a restriction enzyme. Thus, a sample is treated with a restriction enzyme and the products are incubated with an appropriately designed capture moiety. The upper panel of Figure 3 illustrates that uncut strand 40' will not be stably bound to the capture moiety 10", as indicated by the equilibrium arrows showing that the hybridization of uncut strands 40' to capture moieties 10" is unfavorable. In the lower panel of Figure 3, the equilibrium arrows depict the favored binding of cut strands 48 to capture moieties 10", while the unlabeled fragments 49 are not bound to 10". By detecting the label 52' of bound products 48, the presence of the target sequence is detected. The optional duplex-binding-ligand binding site 30" is also shown. This scheme allows the methods of the invention to be used for the detection of nucleic acid sequences which do not occur near the terminus of an intact target strand.
  • Another method of detection is shown in Figure 4. In this example, which is related to "sandwich" assays and is particularly useful for detection of products resulting from the ligation of probes 40' and 44' through phosphate 42, the capture moiety 10"' (which is immobilized on insoluble support 15) is complementary to a region of only one probe, illustratively probe 44'. A secondary probe 50' (called the detector probe) is labeled with a label moiety 52' and is complementary to a region of the probe 40'. As illustrated in the upper reaction scheme of Figure 4, a plurality of unligated probes 44' hybridize to the capture moieties 10"', but are not labelled and so are not detected. Unligated probes 40' are washed away. As the lower reaction scheme of Figure 4 illustrates, the ligation product 45' of the probes 40' and 44' is bound to the capture moiety 10"' and the detector probe 50' hybridizes to region 47 of ligation product 45'; thus, only the ligated product is detected. The optional duplex-binding-ligand binding site 30'" is also shown.
  • It will apparent to the skilled artisan that other schemes for detecting target nucleic acids with the capture moieties of the invention are possible. For example, the target nucleic acid can be amplified before or after hybridization with the capture moiety to improve sensitivity.
  • Many labels are useful for detecting binding of target nucleic acids to capture moieties according to the present invention. Among methods known in the art are the use of radioisotopes (for example, 32P), fluorescent labels, enzymes (such as alkaline phosphatase and horseradish peroxidase, which can be used in colorimetric methods), antibodies, chemiluminescence, bioluminescence, and the like. In a preferred embodiment, a colorimetric method is used to detect target strand binding to a capture moiety. As previously described, labels can be attached to the capture moiety, the target nucleic acid, or a secondary probe, according to the desired method of detection. In certain embodiments, binding of a target strand to a capture moiety can be detected by chromatographic or electrophoretic methods, although this not preferred.
  • While the methods of the invention are easily performed manually, they are readily adapted to use with automated equipment. For example, robotic workstations are available which are capable of performing multiple analyses in parallel through the use of automated pipetting and automated plate readers for use with multi-well plates (described in more detail in Example 5, infra). Thus, in a preferred embodiment, the methods of the invention are performed with automated equipment. The use of automated equipment allows rapid, inexpensive analysis of single or multiple samples, for one or more target nucleic acid sequences.
  • Also described is a reaction mixture. In one example,
    the reaction mixture includes one or more of the following: an immobilized hairpin, a solid or insoluble support, a non-immobilized hairpin, a target nucleic acid strand, a sequence-specific duplex-binding ligand, a non-sequence-specific duplex-binding ligand, a duplex-binding ligand which does not create or cleave any covalent bond, a duplex denaturant a standard. The reaction mixture can be a solution.
  • Further described is a kit for the detection of a target nucleic acid. In one example the kit includes one or more of the following: an immobilized hairpin, a non-immobilized hairpin, a solid or insoluble support, a standard, a sequence-specific duplex-binding ligand, a non-sequence-specific duplex-binding ligand, a duplex-binding ligand which does not create or cleave any covalent bond, a duplex denaturant, instructions for use. The term "standard", as used herein, refers to a nucleic acid strand which is pre-selected to be substantially complementary to a single-stranded region of a capture moiety.
  • Exemplification Example 1
  • To test the ability of a nucleic acid hairpin capture moiety to discriminate between a "cut" oligonucleotide and an intact oligonucleotide under varying conditions of duplex-binding ligand and duplex denaturant, the following experiments were performed.
  • The radioisotopically-labelled 13-mer Probe 1 (the "cut" probe) 5'-CAGCG CGTTT TAG-3' (SEQ ID NO.3) and 17-mer Probe 2 (the "uncut" probe) 5'-CAGCG CGTTT TAGCT TA-3' (SEQ ID NO. 4) were synthesized by standard protocols on a commercially available oligonucleotide synthesizer (Applied Biosystems ABI-380B). The immobilized nucleic acid hairpin was provided in the following manner: 1 mg of prewashed streptavidin-coated magnetic beads (available from Dynal) in 200 µl of BN buffer (1M NaCl/1mM EDTA/ 0.025% Triton-X 100/ 10mM Tris HCl, pH 7.5) was incubated with 500 pmol of the biotinylated hairpin (synthesized on an DNA synthesizer; the biotinylated bases were obtained from Glen Research) for one hour at room temperature with gentle rotation. The biotinylated hairpin had the following structure:
    Figure imgb0003
    The hairpin and probe were chosen so that hybridization of the complementary probe with the hairpin forms a binding site for the duplex-binding ligand Actinomycin D (e.g., 5'-AGCT-3'). The beads were then washed three times with BN buffer to remove unattached hairpin. Separate experiments with radiolabelled biotinylated hairpin established that about 20% (200 pmol) of the hairpin was bound to the beads.
  • For each experiment, 20 µg of beads with immobilized hairpin (about 2 pmol hairpin per experiment) was incubated with 20,000 CPM (about 2 fmol) in 20 µl of BN buffer for one hour. The beads were then washed three times with buffer containing urea and/or Actinomycin D at varying concentrations (see Figure 5), The beads were then removed from the buffer with a magnet. Cerenkov counting of the beads and of the combined buffer and washes on a scintillation counter allowed calculation of the percent binding as CPM(beads)/[CPM(beads) + CPM(buffer)].
  • The results are shown in Figure 5. It is clear that, as expected, as the concentration of a duplex denaturant (urea) is increased, the amount of bound oligonucleotide decreases (Figure 5A). Importantly, binding of the "uncut" 17-mer drops off more sharply than binding of the "cut" 13-mer, so discrimination between the cut and uncut oligonucleotides increases at higher duplex denaturant concentrations. At a fixed concentration of urea, increasing amounts of Actinomycin D (a duplex-binding ligand) result in increased binding of both the cut and uncut oligonucleotides, and discrimination between the two oligonucleotides decreases (Figure 5B). This result is also expected. Finally, Figure 5C shows the effect of holding the concentration of Actinomycin D constant while varying the concentration of urea; the figure demonstrates that oligonucleotide discrimination under these conditions is highest at about 8M urea.
  • These results clearly show that cut and uncut oligonucleotide can be discriminated, and that the level of discrimination can be adjusted by changing the concentration of duplex-binding ligand or duplex denaturant.
  • Example 2
  • The effect of wash buffer salt concentration on oligonucleotide binding, and the ability of the hairpin moiety to discriminate between a complementary and a non-complementary oligonucleotide, were tested in the following experiments.
  • The 13-mer Probe 1 (SEQ ID NO. 3), the 17-mer Probe 2 (SEQ ID NO. 4), and the hairpin capture moiety were prepared as in Example 1. The non-complementary 20-mer 5'-TTATA ATTAA CCGGT ATATA-3' (SEQ ID NO. 6) was also synthesized by standard methods on an automated DNA synthesizer. Binding experiments were performed as described above, except that the beads were washed with 3 wash buffers contained decreasing salt concentrations; the first wash buffer had 1M NaCl, the second wash was with 0.1M NaCl, and the third wash was with 0.01M NaCl. None of the wash buffers contained urea or Actinomycin D.
  • The effect of varying wash buffer salt concentration on complementary/non-complementary discrimination is shown in Figure 6. After the first wash, at high salt concentration, binding of the complementary oligonucleotide is greatest, as expected; the 17-mer has a 4-base segment which cannot bind effectively to the hairpin capture moiety and which destabilizes duplex formation. The subsequent washes at lower salt concentrations result in some washing off of all the oligonucleotides, but discrimination between the complementary oligonucleotide and the non-complementary oligonucleotide is improved. The improved discrimination stems from the large decrease in binding of the noncomplementary oligonucleotide, while the binding of the complementary oligonucleotide is only slightly decreased. Discrimination between the complementary 13-mer and the 17-mer also improves when the salt concentration decreases from 1 M to 0.1 M. Even after the low-salt wash about 70% of the complementary strand remains bound to the capture hairpin.
  • The results of this Example, taken together with the results of Example 1, demonstrate that the concentrations of salt (in the wash buffer), duplex-binding ligand, and duplex denaturant can be manipulated to attain optimal sensitivity or optimal selectivity (discrimination), or a balance between sensitivity and selectivity. This experiment also shows that the binding of target to the hairpin moiety is strong enough to survive relatively high-stringency washes.
  • Example 3
  • The ability of the capture moiety to discriminate between a complementary target strand and a non-complementary strand was tested in the following experiments. The effect of an overhanging "tail" on the target strand was also tested.
  • The hairpin capture moiety used in Example 1 was incubated with one of three oligonucleotides: the 13-mer complementary strand (SEQ ID NO. 3), a 22-mer complementary strand 5'-GGCGT TAACC AGCGC GTTTT AG-3' (SEQ ID NO. 7), and a non-complementary 26-mer strand 5'-TACCG GAAGG AATTC TTCGT GCATG A-3' (SEQ ID NO. 8). The experiments were performed as described in Example 1. The probes were tested at several copy numbers. The results are shown in Figure 7.
  • As shown in Figures 7A and 7B, the complementary strands (both the 13-mer and the 22-mer, which has an unpaired 9-base "tail") bind well to the capture hairpin. This result shows that the 9-mer "tail", which is not close to the "stem" or intramoecular duplex region of the capture moiety, has very little effect on target binding efficiency (in contrast to the "uncut" probe of Example 2, which had an unpaired end close to the stem of the capture moiety and which was significantly destabilized). The 26-mer non-complementary probe, as expected, shows very little binding to the capture moiety (<2%) (Figure 7C). These results demonstrate that the capture moiety can efficiently discriminate between target and non-target sequences.
  • Example 4
  • The ability of the capture moieties to capture and detect the products of a ligation reaction was demonstrated in the following example.
  • The target sequence was a 32-mer 5'-ATTTT TTGCA AATTT TTATT TGCCC GAGTA TA-3' (SEQ ID NO. 9) which corresponds to the E. coli rhsA gene. The two probes complementary to the product, probe 1 (17-mer) and probe 2 (15-mer), are shown below.
    Probe 1: 5'-TTATT TGCCC GAGTA TA-3' SEQ ID NO. 10
    Probe 2: 5'-ATTTT TTGCA AATTT-3' SEQ ID NO. 11
  • Probe 1 was 5'-phosphorylated with 32P following a standard kinasing protocol. The ligation reactions were performed in a microcentrifuge tube with 0.1 nmol Probe 2 and 20,000 CPM Probe 1 (about 1 fmol) in buffer (50mM Tris-HCl, pH 7.8, 10mM MgCl2, 10mM dithiothreitol, 25 ug/ml bovine serum albumin, 1 mM ATP), total volume 20 µl. The target concentration was varied from 0.1 µM to 1 fM in 10-fold steps. Samples were annealed by heating to 90° for 5 minutes, and then cooled to room temperature. T4 ligase (400 units) was added (except to the no enzyme control) and the samples incubated at 37° for 2-4 hours. The ligase was inactivated by heating to 90° for 5 minutes.
  • 20 µg of streptavidin-coated magnetic microbeads in 20 µl of BN buffer were then added to the ligation reaction mixture. The beads were previously derivatized with the biotinylated hairpin capture moiety shown below:
    Figure imgb0004
  • The beads had a total of about 4 pmol of immobilized hairpin capture moiety. The samples were incubated for 20-30 minutes at room temperature with gentle rotation, and then were separated from the buffer with a magnet and washed three times with BN buffer. The products were then separated by polyacrylamide gel electrophoresis. Films were exposed for 24 hours. Control samples which were not treated with the hairpin capture moiety were also analyzed.
  • The results are shown in Figures 8 and 9. The bottom panel of Figure 8 shows the band pattern of the reaction mixture before treatment with the hairpin capture moiety (control mixture). The lower band is unreacted probe; the main upper band is the ligated product. The small band at high copy numbers is an artifact. Ligated product is visible at 104 copies of target. The upper panel of Figure 8 shows the band pattern of the reaction products bound to the capture moiety. Very little unligated probe is seen, demonstrating the high selectivity of the system for the ligated product. Furthermore, the sensitivity of the system is almost the same as in the control mixture (lower panel), namely about 104-105 copies of target (the grainy pattern seen in several lanes of the upper panel is an unrelated artifact). Note that at high target copy number the amount of ligated product captured by the hairpin decreases; this is believed to be due to the presence of excess target, which competes for the ligated product.
  • Figure 9 shows a similar experiment performed with 800 units of T4 ligase. The results are similar to Figure 8. The lane labelled "109" in the lower panel resulted from a flawed experiment.
  • Example 5
  • This Example describes the use of multi-well plates for automated screening of samples for multiple target nucleic acid sequences.
  • Biotinylated DNA hairpins are synthesized according to the methods described in Example 1. One DNA hairpin sequence is synthesized for each target sequence of interest. For example, in screening for cystic fibrosis, several sequences which correspond to different mutations and are diagnostic for the disease would be used.
  • Each well of a 96-well plate is coated with streptavidin as described in, for example, U.S. Patent No. 5,374,524 to Miller , and a plurality of biotinylated hairpins of one sequence are immobilized in each well. Unbound hairpins are removed by washing with buffer, and the prepared 96-well plate is placed in a robotic workstation. The workstation is programmed to add 100 µl of buffer to each well. The buffer contains urea (5M) and Actinomycin D (400µM). Addition of buffer is followed by addition of 10 µl of a solution of sample DNA. The 96-well plate is incubated at room temperature for one hour, and the reaction mixture is then removed from each well by automated pipet. The wells are rinsed three times with buffer to remove unbound DNA. Then a solution containing a secondary probe, which is complementary to a region of the target sequence and has been labelled by covalent attachment of alkaline phosphatase according to well-known techniques, is added. The samples are again incubated, and the unhybridized probe is removed. The wells are rinsed with buffer and then treated with a solution of BCIP (5-bromo-4-chloro-3-indolylphosphate) and NBT (nitroblue tetrazolium). Wells having hairpins which bound to the sample DNA will develop a blue color which can be read by a conventional plate reader.
  • This assay is rapid, specific, uses standard equipment, and can easily be modified to detect any desired target nucleic acid.
  • Example 6
  • The ability of a hairpin capture moiety to discriminate single base mismatches was test in the following experiment.
  • The immobilized hairpin of Example 1 (SEQ ID NO. 5) was used to capture the matched probe of Example 1 (SEQ ID NO. 3) and mismatched probes identical to the matched probe except that the 3'- terminal base was either C, A, or T, as shown in Figure 10. The experimental conditions were as set out in Example 1. The results are shown in Figure 11, which depicts the fraction of melted duplex as a function of temperature.
  • As can be seen from Figure 11, substituting an A or T at the 3' terminal of the target strand lowers the melting temperature of the target:capture moiety duplex significantly. Thus, discrimination of single-base mismatches in the target is possible. Interestingly, substitution of C at the 3'-terminus of the target does not lower the melting temperature of the duplex significantly in this case.
  • SEQUENCE LISTING
    • (1) GENERAL INFORMATION:
      • (i) APPLICANT: Michael J. Lane; Albert S. Benight and Brian D. Faldasz
      • (ii) TITLE OF INVENTION: Nucleic Acid Capture Moieties
      • (iii) NUMBER OF SEQUENCES: 12
      • (iv) CORRESPONDENCE ADDRESS:
        1. (A) ADDRESSEE: LAHIVE & COCKFIELD
        2. (B) STREET: 60 State Street, Suite 510
        3. (C) CITY: Boston
        4. (D) STATE: Massachusetts
        5. (E) COUNTRY: USA
        6. (F) ZIP: 02109-1875
      • (v) COMPUTER READABLE FORM:
        1. (A) MEDIUM TYPE: Floppy disk
        2. (B) COMPUTER: IBM PC compatible
        3. (C) OPERATING SYSTEM: PC-DOS/MS-DOS
        4. (D) SOFTWARE: Patent In Release #1.0, Version #1.25
      • (vi) CURRENT APPLICATION DATA:
        (A) APPLICATION NUMBER: US 08/519,197 (B) FILING DATE: 25-AUG-1995
      • (viii) ATTORNEY/AGENT INFORMATION:
        • (A) NAME: Louis Myers
        • (B) REGISTRATION NUMBER: 35,965
        • (C) REFERENCE/DOCKET NUMBER: TMI-012
      • (ix) TELECOMMUNICATION INFORMATION:
        1. (A) TELEPHONE: (617)227-7400
        2. (B) TELEFAX: (617)227-5941
    • (2) INFORMATION FOR SEQ ID NO:1:
      • (i) SEQUENCE CHARACTERISTICS:
        1. (A) LENGTH: 38 base pairs
        2. (B) TYPE: nucleic acid
        3. (C) STRANDEDNESS: single
        4. (D) TOPOLOGY: linear
      • (ii) MOLECULE TYPE: cDNA
      • (ix) FEATURE:
        • (A) NAME/KEY: modified_base
        • (B) LOCATION: 19
        • (D) OTHER INFORMATION: /note= "Biotinylated thymidine"
      • (ix) FEATURE:
        • (A) NAME/KEY: misc_feature
        • (B) LOCATION: 38
        • (D) OTHER INFORMATION: /note= "N represents between 4 and 50 additional bases."
      • (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:
        CTAGTCGACG TGGTCCTTTT TGGACCACGT CGACTAGN    38
    • (2) INFORMATION FOR SEQ ID NO:2:
      • (i) SEQUENCE CHARACTERISTICS:
        1. (A) LENGTH: 38 base pairs
        2. (B) TYPE: nucleic acid
        3. (C) STRANDEDNESS: single
        4. (D) TOPOLOGY: linear
      • (ii) MOLECULE TYPE: cDNA
      • (ix) FEATURE:
        • (A) NAME/KEY: modified_base
        • (B) LOCATION: 20
        • (D) OTHER INFORMATION: /note= "Biotinylated thymidine"
      • (ix) FEATURE:
        • (A) NAME/KEY: misc_feature
        • (B) LOCATION: 1
        • (D) OTHER INFORMATION: /note= "N represents between 4 and 50 additional bases."
      • (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:
        NTCTAGCGAC GTGGTCCTTT TTGGACCACG TCGACTAG    38
    • (2) INFORMATION FOR SEQ ID NO:3:
      • (i) SEQUENCE CHARACTERISTICS:
        1. (A) LENGTH: 13 base pairs
        2. (B) TYPE: nucleic acid
        3. (C) STRANDEDNESS: single
        4. (D) TOPOLOGY: linear
      • (ii) MOLECULE TYPE: cDNA
      • (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:
        CAGCGCGTTT TAG    13
    • (2) INFORMATION FOR SEQ ID NO:4:
      • (i) SEQUENCE CHARACTERISTICS:
        1. (A) LENGTH: 17 base pairs
        2. (B) TYPE: nucleic acid
        3. (C) STRANDEDNESS: single
        4. (D) TOPOLOGY: linear
      • (ii) MOLECULE TYPE: cDNA
      • (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:
        CAGCGCGTTT TAGCTTA    17
    • (2) INFORMATION FOR SEQ ID NO:5:
      • (i) SEQUENCE CHARACTERISTICS:
        1. (A) LENGTH: 50 base pairs
        2. (B) TYPE: nucleic acid
        3. (C) STRANDEDNESS: single
        4. (D) TOPOLOGY: linear
      • (ii) MOLECULE TYPE: cDNA
      • (ix) FEATURE:
        • (A) NAME/KEY: modified_base
        • (B) LOCATION: 19
        • (D) OTHER INFORMATION: /note= "Biotinylated thymidine"
      • (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:
        CTAGTCGACG TGGTCCTTTT TGGACCACGT TGGACCACGT CGACTAGCTA AAACGCGCTG    50
    • (2) INFORMATION FOR SEQ ID NO:6:
      • (i) SEQUENCE CHARACTERISTICS:
        1. (A) LENGTH: 20 base pairs
        2. (B) TYPE: nucleic acid
        3. (C) STRANDEDNESS: single
        4. (D) TOPOLOGY: linear
      • (ii) MOLECULE TYPE: cDNA
      • (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:
        TTATAATTAA CCGGTATATA    20
    • (2) INFORMATION FOR SEQ ID NO:7:
      • (i) SEQUENCE CHARACTERISTICS:
        1. (A) LENGTH: 22 base pairs
        2. (B) TYPE: nucleic acid
        3. (C) STRANDEDNESS: single
        4. (D) TOPOLOGY: linear
      • (ii) MOLECULE TYPE: cDNA
      • (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:
        GGCGTTAACC AGCGCGTTTT AG    22
    • (2) INFORMATION FOR SEQ ID NO:8:
      • (i) SEQUENCE CHARACTERISTICS:
        1. (A) LENGTH: 25 base pairs
        2. (B) TYPE: nucleic acid
        3. (C) STRANDEDNESS: single
        4. (D) TOPOLOGY: linear
      • (ii) MOLECULE TYPE: cDNA
      • (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:
        TACCGGAAGG AATTCTTCGT GCATG    25
    • (2) INFORMATION FOR SEQ ID NO:9:
      • (i) SEQUENCE CHARACTERISTICS:
        1. (A) LENGTH: 32 base pairs
        2. (B) TYPE: nucleic acid
        3. (C) STRANDEDNESS: single
        4. (D) TOPOLOGY: linear
      • (ii) MOLECULE TYPE: cDNA
      • (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:
        ATTTTTTGCA AATTTTTATT TGCCCGAGTA TA    32
    • (2) INFORMATION FOR SEQ ID NO:10:
      • (i) SEQUENCE CHARACTERISTICS:
        1. (A) LENGTH: 17 base pairs
        2. (B) TYPE: nucleic acid
        3. (C) STRANDEDNESS: single
        4. (D) TOPOLOGY: linear
      • (ii) MOLECULE TYPE: cDNA
      • (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:
        TTATTTGCCC GAGTATA    17
    • (2) INFORMATION FOR SEQ ID NO:11:
      • (i) SEQUENCE CHARACTERISTICS:
        1. (A) LENGTH: 15 base pairs
        2. (B) TYPE: nucleic acid
        3. (C) STRANDEDNESS: single
        4. (D) TOPOLOGY: linear
      • (ii) MOLECULE TYPE: cDNA
      • (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:
        ATTTTTTGCA AATTT    15
    • (2) INFORMATION FOR SEQ ID NO:12:
      • (i) SEQUENCE CHARACTERISTICS:
        1. (A) LENGTH: 52 base pairs
        2. (B) TYPE: nucleic acid
        3. (C) STRANDEDNESS: single
        4. (D) TOPOLOGY: linear
      • (ii) MOLECULE TYPE: cDNA
      • (ix) FEATURE:
        • (A) NAME/KEY: modified_base
        • (B) LOCATION: 34
        • (D) OTHER INFORMATION: /note= "Biotinylated thymidine"
      • (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:
        AAATTTGCAA AAAATCTAGT CGACGTGGTC CTTTTTGGAC CACGTCGACT AG    52

Claims (13)

  1. A method of capturing a target single-stranded nucleic acid sequence on a solid support, the method comprising the steps of:
    (a) providing a nucleic acid capture moiety immobilized on the solid support, the nucleic acid capture moiety comprising a structure A-B-C-D wherein
    A is a nucleic acid sequence;
    B and D are nucleic acid sequences which are capable of hybridising to each other to form an intramolecular duplex; and
    C is a linker; which covalently links B and D;
    wherein A is complementary to the target single-stranded nucleic acid sequence;
    (b) forming a reaction mixture comprising said target single-stranded nucleic acid and said nucleic acid capture moiety under conditions such that the target single-stranded nucleic acid and the nucleic acid capture moiety can hybridize to form an intermolecular duplex; and
    (c) capturing the target single-stranded nucleic acid on the solid support by hybridizing the target single-stranded nucleic acid to said immobilized nucleic acid capture moiety to separate the target single-stranded nucleic acid hybridized to the nucleic acid capture moiety from the reaction mixture;
    wherein stability of the intermolecular duplex is increased by base stacking between a terminal base of the nucleic acid capture moiety and a terminal base of the target single-stranded nucleic acid which forms a part of the intermolecular duplex.
  2. The method of claim 1 further comprising the step of detecting the presence or absence of the target single-stranded nucleic acid hybridized to the nucleic acid capture moiety.
  3. The method of claim 1 or 2, wherein the target single-stranded nucleic acid and the capture moiety, when hybridized, comprises at least one duplex-binding-ligand binding site and
    wherein the reaction mixture further comprises one or more duplex-binding ligands.
  4. The method of claim 3 wherein hybridization of the target single-stranded nucleic acid to the nucleic acid capture moiety forms a nicked duplex.
  5. The method of claim 4 wherein one of the at least one duplex-binding ligand binding sites includes the nick.
  6. The method of claim 4 wherein one of the at least one duplex-binding-ligand binding sites does not include the nick.
  7. The method of any one of claims 3 to 6 wherein the intermolecular duplex comprises one of the at least one duplex-binding-ligand binding sites.
  8. The method of any one of claims 3 to 7, wherein the duplex-binding ligand is sequence-specific.
  9. The method of any one of claims 3 to 8, wherein the duplex-binding ligand does not covalently modify any duplex.
  10. The method of any one of claims 3 to 9 wherein binding of the duplex-binding ligand to the duplex-binding-ligand-binding site promotes the hybridization of the target single-stranded nucleic acid and the nucleic acid capture moiety.
  11. The method of any one of claims 3 to 10 wherein a first base pair of the intermolecular duplex formed by the target single-stranded nucleic acid and A encodes part of the at least one duplex-binding-ligand binding site.
  12. A method of promoting hybridization of a target single-stranded nucleic acid and an immobilized nucleic acid capture moiety, the method comprising the steps of:
    (a) providing an immobilized unimolecular nucleic acid capture moiety having a double-stranded region and an adjacent single-stranded region, said single-stranded region being capable of hybridizing to said target single-stranded nucleic acid;
    (b) forming a reaction mixture comprising said target single-stranded nucleic acid, said immobilized nucleic acid capture moiety, and a duplex-binding ligand, under conditions such that the target single-stranded nucleic acid and the immobilized nucleic acid capture moiety can hybridize; and
    (c) allowing said target single-stranded nucleic acid to hybridize to said immobilized nucleic acid capture moiety to form an intermolecular duplex, wherein the intermolecular duplex comprises a duplex-binding-ligand binding site, such that said duplex-binding ligand binds to said duplex-binding ligand binding site,
    whereby binding of the duplex-binding ligand to the duplex-binding-ligand binding site promotes hybridization of the target single-stranded nucleic acid and the immobilized nucleic acid capture moiety, wherein base stacking between a terminal base of the immobilized nucleic acid capture moiety and a terminal base of the target single-stranded nucleic acid increases stability of said intermolecular duplex.
  13. The method of claim 12, wherein the duplex-binding ligand is sequence-specific.
EP96928976A 1995-08-25 1996-08-23 Nucleic acid capture moieties Expired - Lifetime EP0861262B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US519197 1990-05-03
US08/519,197 US5770365A (en) 1995-08-25 1995-08-25 Nucleic acid capture moieties
PCT/US1996/013546 WO1997008183A1 (en) 1995-08-25 1996-08-23 Nucleic acid capture moieties

Publications (3)

Publication Number Publication Date
EP0861262A1 EP0861262A1 (en) 1998-09-02
EP0861262A4 EP0861262A4 (en) 2000-07-12
EP0861262B1 true EP0861262B1 (en) 2008-10-22

Family

ID=24067290

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96928976A Expired - Lifetime EP0861262B1 (en) 1995-08-25 1996-08-23 Nucleic acid capture moieties

Country Status (9)

Country Link
US (1) US5770365A (en)
EP (1) EP0861262B1 (en)
JP (1) JP2001517068A (en)
KR (1) KR19990044342A (en)
AT (1) ATE412002T1 (en)
AU (1) AU701632B2 (en)
CA (1) CA2227950A1 (en)
DE (1) DE69637726D1 (en)
WO (1) WO1997008183A1 (en)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6468742B2 (en) 1993-11-01 2002-10-22 Nanogen, Inc. Methods for determination of single nucleic acid polymorphisms using bioelectronic microchip
US7582421B2 (en) * 1993-11-01 2009-09-01 Nanogen, Inc. Methods for determination of single nucleic acid polymorphisms using a bioelectronic microchip
DE19527155C2 (en) * 1995-07-25 1998-12-10 Deutsches Krebsforsch Method of sequencing by oligomer hybridization
DE69719057T2 (en) 1996-07-12 2003-12-04 Tm Technologies Inc., Woburn PROCESS FOR GAINING SIGNALS
EP1025120B1 (en) 1997-10-27 2010-08-18 Boston Probes, Inc. Methods, kits and compositions pertaining to pna molecular beacons
US6485901B1 (en) 1997-10-27 2002-11-26 Boston Probes, Inc. Methods, kits and compositions pertaining to linear beacons
DE19808884A1 (en) * 1998-03-03 1999-09-16 November Ag Molekulare Medizin Apparatus and method for detecting chemical substances
US6361942B1 (en) * 1998-03-24 2002-03-26 Boston Probes, Inc. Method, kits and compositions pertaining to detection complexes
WO1999063077A2 (en) * 1998-06-04 1999-12-09 Tm Technologies, Inc. Compositions of nucleic acid which alter ligand-binding characteristics and related methods and products
GB0002310D0 (en) * 2000-02-01 2000-03-22 Solexa Ltd Polynucleotide sequencing
US20100130368A1 (en) * 1998-07-30 2010-05-27 Shankar Balasubramanian Method and system for sequencing polynucleotides
US20040106110A1 (en) * 1998-07-30 2004-06-03 Solexa, Ltd. Preparation of polynucleotide arrays
US20030022207A1 (en) * 1998-10-16 2003-01-30 Solexa, Ltd. Arrayed polynucleotides and their use in genome analysis
US6787308B2 (en) 1998-07-30 2004-09-07 Solexa Ltd. Arrayed biomolecules and their use in sequencing
US7244570B2 (en) 1998-08-04 2007-07-17 Luminex Molecular Diagnostics, Inc. Methods and compositions for modulating “marginally indiscriminant” hybridizations
WO2000008211A2 (en) * 1998-08-04 2000-02-17 Tm Technologies, Inc. Methods and compositions for modulating 'marginally indiscriminant' hybridizations
WO2000026412A1 (en) * 1998-11-02 2000-05-11 Kenneth Loren Beattie Nucleic acid analysis using sequence-targeted tandem hybridization
US7790865B1 (en) 1999-02-02 2010-09-07 Qiagen North American Holdings, Inc Eluting reagents, methods and kits for isolating DNA
AU769929B2 (en) * 1999-04-12 2004-02-12 Nanogen, Inc. Methods for determination of single nucleic acid polymorphisms using a bioelectronic microchip
US8137906B2 (en) * 1999-06-07 2012-03-20 Sloning Biotechnology Gmbh Method for the synthesis of DNA fragments
US6964847B1 (en) 1999-07-14 2005-11-15 Packard Biosciences Company Derivative nucleic acids and uses thereof
CA2383264A1 (en) * 1999-08-13 2001-02-22 Yale University Binary encoded sequence tags
US6528319B1 (en) 1999-09-02 2003-03-04 Amersham Biosciences Corp Method for anchoring oligonucleotides to a substrate
US6924108B2 (en) 1999-12-21 2005-08-02 Ingeneus Corporation Nucleic acid binding enhancement by conjugation with nucleotides, nucleosides, bases and/or their analogues
AU2001267191A1 (en) * 2000-06-06 2001-12-17 Tm Bioscience Corporation Capture moieties for nucleic acids and uses thereof
US6664079B2 (en) 2000-10-06 2003-12-16 The Trustees Of Columbia University In The City Of New York Massive parallel method for decoding DNA and RNA
US9708358B2 (en) 2000-10-06 2017-07-18 The Trustees Of Columbia University In The City Of New York Massive parallel method for decoding DNA and RNA
US20040266021A9 (en) * 2001-01-26 2004-12-30 Andras Guttman Multicapillary fraction collection system and method
US20030032028A1 (en) * 2001-06-12 2003-02-13 Gayle Dace In vitro capture of nucleic acids via modified oligonucleotides and magnetic beads
US20020187479A1 (en) * 2001-06-12 2002-12-12 Gayle Dace In vitro capture of nucleic acids via modified oligonucleotides and magnetic beads
US20030082584A1 (en) * 2001-06-29 2003-05-01 Liang Shi Enzymatic ligation-based identification of transcript expression
US20030170695A1 (en) * 2001-06-29 2003-09-11 Liang Shi Enzymatic ligation-based identification of nucleotide sequences
EP1314783B1 (en) * 2001-11-22 2008-11-19 Sloning BioTechnology GmbH Nucleic acid linkers and their use in gene synthesis
CA2478985A1 (en) * 2002-03-13 2003-09-25 Syngenta Participations Ag Nucleic acid detection method
US7601493B2 (en) * 2002-07-26 2009-10-13 Nanogen, Inc. Methods and apparatus for screening and detecting multiple genetic mutations
US7291459B2 (en) * 2002-12-10 2007-11-06 University Of Alabama At Huntsville Nucleic acid detector and method of detecting targets within a sample
US7851150B2 (en) * 2002-12-18 2010-12-14 Third Wave Technologies, Inc. Detection of small nucleic acids
US8206904B2 (en) * 2002-12-18 2012-06-26 Third Wave Technologies, Inc. Detection of nucleic acids
US20050014134A1 (en) * 2003-03-06 2005-01-20 West Jason Andrew Appleton Viral identification by generation and detection of protein signatures
US20050074781A1 (en) * 2003-10-02 2005-04-07 Herbert von Schroeder Nucleic acid braided J-probes
US20050095602A1 (en) * 2003-11-04 2005-05-05 West Jason A. Microfluidic integrated microarrays for biological detection
GB0326073D0 (en) 2003-11-07 2003-12-10 Solexa Ltd Improvements in or relating to polynucleotide arrays
JP4675330B2 (en) 2003-11-14 2011-04-20 デューク ユニバーシティ Charcot-Marie-Tooth disease type 2A detection method
US20050147976A1 (en) * 2003-12-29 2005-07-07 Xing Su Methods for determining nucleotide sequence information
GB0400584D0 (en) * 2004-01-12 2004-02-11 Solexa Ltd Nucleic acid chacterisation
ATE483020T1 (en) * 2004-01-23 2010-10-15 Sloning Biotechnology Gmbh ENZYMATIC PRODUCTION OF NUCLEIC ACID MOLECULES
US7618778B2 (en) 2004-06-02 2009-11-17 Kaufman Joseph C Producing, cataloging and classifying sequence tags
EP1778867B1 (en) * 2004-07-01 2010-04-28 Gen-Probe Incorporated Methods and compositions to detect nucleic acids in a biological sample
US7620402B2 (en) * 2004-07-09 2009-11-17 Itis Uk Limited System and method for geographically locating a mobile device
US7524672B2 (en) * 2004-09-22 2009-04-28 Sandia Corporation Microfluidic microarray systems and methods thereof
US7592139B2 (en) 2004-09-24 2009-09-22 Sandia National Laboratories High temperature flow-through device for rapid solubilization and analysis
US20070015176A1 (en) * 2005-02-18 2007-01-18 Applera Corporation Small nucleic acid detection probes and uses thereof
US9297036B2 (en) 2005-07-01 2016-03-29 Agilent Technologies, Inc Nucleic acid probes for analysis of small RNAs and other polynucleotides
US20070099193A1 (en) * 2005-11-01 2007-05-03 Hui Wang Probe/target stabilization with add-in oligo
US8551697B1 (en) 2005-12-09 2013-10-08 Applied Biosystems, Llc Electrochemical polynucleotide detection comprising ligation
US7754475B2 (en) * 2006-01-25 2010-07-13 Agilent Technologies, Inc. Nucleic acid probes and microarrays for analysis of polynucleotides
US20070172841A1 (en) * 2006-01-25 2007-07-26 Hui Wang Probe/target stabilization with add-in oligo
WO2008069973A2 (en) 2006-12-01 2008-06-12 The Trustees Of Columbia University In The City Of New York Four-color dna sequencing by synthesis using cleavable fluorescent nucleotide reversible terminators
US9938641B2 (en) * 2006-12-18 2018-04-10 Fluidigm Corporation Selection of aptamers based on geometry
EP4310194A3 (en) 2007-10-19 2024-10-16 The Trustees of Columbia University in the City of New York Design and synthesis of cleavable fluorescent nucleotides as reversible terminators for dna sequencing by synthesis
DK2725107T3 (en) 2007-10-19 2019-01-02 Univ Columbia DNA Sequencing with Non-Fluorescent Nucleotide Reversible Terminators and ddNTPs Modified by Split Label and Nucleic Acid comprising Inosine with Reversible Terminators
AU2009225835B2 (en) * 2008-03-15 2013-02-14 Hologic, Inc. Compositions and methods for analysis of nucleic acid molecules during amplification reactions
US9115352B2 (en) * 2008-03-31 2015-08-25 Sloning Biotechnology Gmbh Method for the preparation of a nucleic acid library
JP5733796B2 (en) 2008-05-13 2015-06-10 ジェン−プロウブ インコーポレイテッド Inactivatable target capture oligomers for use in selective hybridization and capture of target nucleic acid sequences
US8399222B2 (en) 2008-11-25 2013-03-19 Gen-Probe Incorporated Compositions and methods for detecting small RNAs, and uses thereof
US8974651B2 (en) 2010-04-17 2015-03-10 C.C. Imex Illuminator for visualization of fluorophores
BR112012028860A2 (en) 2010-05-11 2020-09-01 Dow Agrosciences Llc spnk strains.
ES2625504T3 (en) 2011-05-03 2017-07-19 Dow Agrosciences Llc Integration of genes in the chromosome of Saccharopolyspora spinosa
US20140004523A1 (en) * 2012-06-30 2014-01-02 Justine S. Chow Systems, methods, and a kit for determining the presence of fluids associated with a hydrocarbon reservoir in hydraulic fracturing
JP1628116S (en) 2012-10-24 2019-04-01
US20140322706A1 (en) 2012-10-24 2014-10-30 Jon Faiz Kayyem Integrated multipelx target analysis
DK2914743T3 (en) 2012-11-02 2019-10-14 Life Technologies Corp EXTRACTION, DETECTION AND QUANTIFICATION OF LITTLE RNA
WO2014144883A1 (en) 2013-03-15 2014-09-18 The Trustees Of Columbia University In The City Of New York Raman cluster tagged molecules for biological imaging
EP3034171B1 (en) 2013-03-15 2019-04-24 Genmark Diagnostics Inc. Systems, methods and apparatus for manipulating deformable fluid vessels
US9498778B2 (en) 2014-11-11 2016-11-22 Genmark Diagnostics, Inc. Instrument for processing cartridge for performing assays in a closed sample preparation and reaction system
USD881409S1 (en) 2013-10-24 2020-04-14 Genmark Diagnostics, Inc. Biochip cartridge
US9835587B2 (en) 2014-04-01 2017-12-05 C.C. Imex Electrophoresis running tank assembly
CN104195229A (en) * 2014-07-24 2014-12-10 益善生物技术股份有限公司 Epidermal growth factor receptor inhibitor drug curative effect related gene expression detection liquid chip kit
CN104195232A (en) * 2014-07-24 2014-12-10 益善生物技术股份有限公司 Anti-microtubule chemotherapeutic drug curative effect related gene mRNA expression level liquid chip detection kit
US10005080B2 (en) 2014-11-11 2018-06-26 Genmark Diagnostics, Inc. Instrument and cartridge for performing assays in a closed sample preparation and reaction system employing electrowetting fluid manipulation
JP2018502309A (en) 2014-11-11 2018-01-25 ジェンマーク ダイアグノスティクス, インコーポレイテッド Apparatus and cartridge for performing an assay in a closed sample preparation and reaction system
US9598722B2 (en) 2014-11-11 2017-03-21 Genmark Diagnostics, Inc. Cartridge for performing assays in a closed sample preparation and reaction system
ES2890776T3 (en) 2015-03-13 2022-01-24 Life Technologies Corp Methods, compositions and kits for the capture, detection and quantification of small RNA
US11300578B2 (en) 2016-09-19 2022-04-12 Roche Molecular Systems, Inc. Instrument for processing cartridge for performing assays in a closed sample preparation and reaction system
WO2019011875A1 (en) 2017-07-11 2019-01-17 Qiagen Gmbh QUANTIFICATION OF ANTI SENSE OLIGONUCLEOTIDES (ASOs)
WO2019040769A1 (en) 2017-08-24 2019-02-28 Clinical Micro Sensors, Inc. (dba GenMark Diagnostics, Inc.) Electrochemical detection of bacterial and/or fungal infections
US20190062809A1 (en) 2017-08-24 2019-02-28 Clinical Micro Sensors, Inc. (dba GenMark Diagnostics, Inc.) Electrochemical detection of bacterial and/or fungal infections
CA3138367A1 (en) 2019-04-30 2020-11-05 Encodia, Inc. Methods for preparing analytes and related kits

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995000666A1 (en) * 1993-06-17 1995-01-05 The Research Foundation Of State University Of New York Improved nucleic acid reactions

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4358535A (en) * 1980-12-08 1982-11-09 Board Of Regents Of The University Of Washington Specific DNA probes in diagnostic microbiology
FI63596C (en) * 1981-10-16 1983-07-11 Orion Yhtymae Oy MICROBIA DIAGNOSIS FOERFARANDE SOM GRUNDAR SIG PAO SKIKTSHYBRIDISERING AV NUCLEINSYROR OCH VID FOERFARANDET ANVAENDA KOMBINATIONER AV REAGENSER
US5374524A (en) * 1988-05-10 1994-12-20 E. I. Du Pont De Nemours And Company Solution sandwich hybridization, capture and detection of amplified nucleic acids
WO1991006679A1 (en) * 1989-10-24 1991-05-16 Stratagene An improved method for hybridizing nucleic acids using single-stranded nucleic acid binding protein
US5215899A (en) * 1989-11-09 1993-06-01 Miles Inc. Nucleic acid amplification employing ligatable hairpin probe and transcription
US5387510A (en) * 1991-10-02 1995-02-07 Eastman Kodak Company Detection of amplified nucleic acid using secondary capture oligonucleotides and test kit
US5503980A (en) * 1992-11-06 1996-04-02 Trustees Of Boston University Positional sequencing by hybridization
US5556752A (en) * 1994-10-24 1996-09-17 Affymetrix, Inc. Surface-bound, unimolecular, double-stranded DNA

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995000666A1 (en) * 1993-06-17 1995-01-05 The Research Foundation Of State University Of New York Improved nucleic acid reactions

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ALVI N.K.; RIZVI S.M.; HADI R.Y.: "INTERACTION OF INTERCALATING AND NON-INTERCALATING AGENTS WITH DNA: USE OF HYDROXYAPATITE CHROMATOGRAPHY AND S1 NUCLEASE", CHEMICO-BIOLOGICAL INTERACTIONS, vol. 53, 1985, ELSEVIER SCIENCE IRLAND, IR, pages 219 - 231, XP007902217 *
Carpenter WR. et al.: *dA transcriptionally amplified DNA probe assay with ligatable probes and immunochemical detection*d Clin. Chem. (1993), 39/9 1934-1938. *
KHRAPKO K.R. ET AL: "A method for DNA sequencing by hybridization with oligonucleotide matrix", DNA SEQUENCE, vol. 1, no. 3, January 1991 (1991-01-01), NEW YORK, NY, US, pages 375 - 388, XP000391524 *
RAJASEKARAN BASKARAN ET AL: "Interaction of Spermatid-specific Protein TP2 with Nucleic Acids, in Vitro. A comparative Study with TP1", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 265, no. 34, 5 December 1990 (1990-12-05), AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM, US, pages 21039 - 21047, XP007902218 *
US Patent 5215899 (Miles Inc.) *

Also Published As

Publication number Publication date
US5770365A (en) 1998-06-23
KR19990044342A (en) 1999-06-25
AU701632B2 (en) 1999-02-04
CA2227950A1 (en) 1997-03-06
EP0861262A1 (en) 1998-09-02
WO1997008183A1 (en) 1997-03-06
DE69637726D1 (en) 2008-12-04
EP0861262A4 (en) 2000-07-12
JP2001517068A (en) 2001-10-02
AU6854596A (en) 1997-03-19
ATE412002T1 (en) 2008-11-15

Similar Documents

Publication Publication Date Title
EP0861262B1 (en) Nucleic acid capture moieties
US7914989B2 (en) Capture moieties for nucleic acids and uses thereof
JP3907201B2 (en) HIV probe for use in solution phase sandwich hybridization assays
EP0951565B1 (en) Improved probing of specific nucleic acids
EP0552931B1 (en) Hybridization assay using branched nucleic acid probes
EP0870842B1 (en) Adaptor-tagged competitive PCR
EP0754241B1 (en) Hibridization-ligation assays for the detection of specific nucleic acid sequences
AU2008204338B2 (en) Circular chromosome conformation capture (4C)
EP0745140A1 (en) Circularizing nucleic acid probe able to interlock with a target sequence through catenation
WO1996035699A1 (en) Chemical ligation of template-directed oligonucleotides
EP0849363B1 (en) Method of identifying a nucleic acid using triple helix formation of adjacently annealed probes
JP2008534011A (en) Unique sequence hybridization probe (USP)
EP0857791B1 (en) Method of analysis using signal amplification
WO2000029624A2 (en) Methods and compositions for detection of nucleic acid sequences and signal amplification
CN116745433A (en) Analyte detection methods employing concatemers
JP2006508677A (en) Oligonucleotide-induced analysis of gene expression
CA2218440A1 (en) Method of analysis using signal amplification
JP2002017399A (en) Method of detecting base polymorphism
AU684915C (en) Hibridization-ligation assays for the detection of specific nucleic acid sequences
CA2324787A1 (en) Personal gene library

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19980324

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: TM TECHNOLOGIES INC.

RIN1 Information on inventor provided before grant (corrected)

Inventor name: FALDASZ, BRIAN D.

Inventor name: BENIGHT, ALBERT S.

Inventor name: LANE, MICHAEL J.

A4 Supplementary search report drawn up and despatched

Effective date: 20000531

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20010206

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: LUMINEX MOLECULAR DIAGNOSTICS, INC.

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 69637726

Country of ref document: DE

Date of ref document: 20081204

Kind code of ref document: P

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090202

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20081022

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090323

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20081022

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20081022

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20081022

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090122

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20081022

26N No opposition filed

Effective date: 20090723

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090831

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090831

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090831

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090823

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090123

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20100813

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20100901

Year of fee payment: 15

Ref country code: DE

Payment date: 20100823

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20100908

Year of fee payment: 15

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090823

REG Reference to a national code

Ref country code: NL

Ref legal event code: V1

Effective date: 20120301

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20110823

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20120430

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120301

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 69637726

Country of ref document: DE

Effective date: 20120301

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110831

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110823

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120301